

## Burden of stroke and risk attributed to smoking in Iran: A Global Burden of Disease Study 2021

Moien AB Khan<sup>1</sup>, Sohrab Amiri<sup>2</sup>

<sup>1</sup>Department of Family Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates <sup>2</sup>Spiritual Health Research Center, Lifestyle Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

#### ABSTRACT

**Objectives:** This study aimed to provide a report and update on the burden of stroke in Iran and globally and to provide new estimates of disability-adjusted life years (DALYs) and stroke-related deaths attributed to smoking.

**Materials and methods:** This study was conducted in accordance with the Global Burden of Disease Study 2021. All age and age-standardized estimates of stroke attributed to smoking were calculated for DALYs and death between the years 1990 and 2021. Estimates were based on per 100,000 individuals. The 95% uncertainty interval (UI) was reported for each of the reported estimates.

**Results:** In 2021, 93 (95% UI 89-99) million stroke cases were detected globally, and 787,178 (95% UI 726,667-855,320) cases were detected in Iran. In 2021, global age-standardized death rate of stroke per 100,000 individuals was 87.45 (95% UI 78.92-94.14), while it was 63.89 (95% UI 56.76-69.69) in Iran. Age-standardized DALYs of stroke per 100,000 individuals in 2021 was 1,886.20 (95% UI 1,738.99-2,017.90) globally and 1,229.18 (95% UI 1,119.52-1,332.60) in Iran. Although the prevalence, incidence, mortality, and disability rates of stroke globally and in Iran decreased between 1990 and 2021, the number of cases increased. In 2021, tobacco use was responsible for over one million deaths worldwide (1,077,804 [95% UI 865,541-1,320,753]), including 4,007 (95% UI 3,159-4,972) in Iran. Compared to 1990, there was an increase in the number of deaths caused by smoking globally (0.52[95% UI 0.31-0.79]) and in Iran (0.20 [95% UI 0.06-0.35]).

**Conclusion:** The burden caused by stroke on the health system can be significant. Therefore, it is necessary to address the preventable risk factors of stroke, including smoking, which is a major risk factor.

Keywords: Death, global burden of disease, prevalence, stroke, tobacco smoking.

Diseases, life expectancy, demographic changes, causes of death, and socioeconomic factors are constantly changing in the world.<sup>[1]</sup> Globally, stroke is one of the noncommunicable diseases that significantly affects health<sup>[2]</sup> and is one of the main causes of disability and death worldwide. Stroke remained the second leading cause of death (11.6% of total deaths) and the third cause of death and disability (5.7% of total disability-adjusted life years [DALYs]) in 2019.<sup>[3]</sup> The costs of poststroke care are high, and 34% of healthcare expenditures are related to stroke.<sup>[2,4]</sup> The healthcare cost of a patient with stroke in the USA was estimated to be 140,048.<sup>[5]</sup> The most

recently published Global Burden of Disease (GBD) report on stroke shows that stroke as the third most common cause of death at level 3.<sup>16</sup> The global direct and indirect costs of stroke in 2017 were \$891 billion, equivalent to 1.12% of global GDP (gross domestic product).<sup>[7]</sup> Between 1990 and 2019, the incidence of strokes in the world has increased significantly by 70.0% (67.0-73.0), prevalent strokes increased by 85.0% (83.0-88.0), deaths increased by 43.0% (31.0-55.0), and DALYs increased by 32.0% (22.0-42.0).<sup>[1]</sup> Considering the explosive incidence of stroke, particularly in young groups and in middle-income countries such as Iran, there are concerns in this field.<sup>[8,9]</sup>

©Copyright 2025 by the Turkish Neurological Society Licensed by Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License.

Correspondence: Sohrab Amiri, PhD. Spiritual Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

E-mail: Amirysohrab@yahoo.com

Received: September 10, 2024 Accepted: December 16, 2024 Published online: February 13, 2025

Cite this article as: Khan MAB, Amiri S. Burden of stroke and risk attributed to smoking in Iran: A Global Burden of Disease Study 2021. Turk J Neurol 2025;31(2):159-185. doi: 10.55697/tnd.2025.292.

According to the GBD report, five main causes of stroke were high systolic blood pressure (79.6 million [67.7-90.8] DALYs), high body mass index (34.9 million [22.3-48.6] DALYs), high fasting plasma glucose (28.9 million [19.8-41.5] DALYs), ambient particulate matter pollution (28.7 million [23.4-33.4] DALYs), and smoking (25.3 million [22.6-28.2] DALYs).<sup>[1]</sup> Furthermore, based on the GBD Study 2021, substantial increases in DALYs were attributed to high BMI, high ambient temperature, high fasting plasma glucose, sugar-sweetened beverages, low physical activity, high systolic blood pressure, lead exposure, and diet low in omega-6 polyunsaturated fatty acids.<sup>[6]</sup>

Tobacco use is one of the most important health problems that is associated with many health consequences.<sup>[10]</sup> The tobacco epidemic is one of the biggest health threats in the world, which leads to the death of more than 8 million people every year.[11] Of these, 7 million deaths are directly related to smoking, and 1.3 million are related to exposure to secondhand smoke.<sup>[11]</sup> The global estimate in 2019 showed that 1.14 billion people in the world were smokers, with 7.41 trillion cigarette-equivalents of tobacco in 2019.<sup>[12]</sup> Compared to 1990, the prevalence of smoking has decreased for both sexes, but due to population growth, the number of smokers has increased.<sup>[12]</sup> The role of smoking in mortality and disability is known, with 7.69 million deaths (13.6% of all deaths) and 200 million DALYs (7.89% of all DALYs) attributed to smoking.<sup>[12]</sup> Smoking has been associated with a wide range of health issues, including risk of cancer,<sup>[13,14]</sup> tuberculosis,<sup>[15]</sup> coronary heart disease,<sup>[16]</sup> stroke,<sup>[17-19]</sup> sleep-related issues,<sup>[20]</sup> and physical impairment.<sup>[21]</sup> The health issues with the highest of deaths attributed to tobacco use were ischemic heart disease (1.68 million), chronic obstructive pulmonary disease (1.59 million), tracheal, bronchial, and lung cancer (1.31 million), and stroke (0.931 million).<sup>[12]</sup>

In recent decades, Iran has undergone changes in the demographic and health-related structures, including increased life expectancy, decreased fertility rate, and an aging population, and noncommunicable diseases have become a health challenge that requires a multisectoral approach.<sup>[22-26]</sup> As mentioned, an increasing stroke incidence is observed in Iran,<sup>[8,9,27]</sup> and smoking is one of the main preventable causes of stroke in the world. The present study followed two main objectives. First, the study aimed to provide a report and an update on the incidence, prevalence,

DALYs, and death due to stroke in Iran and globally. The second objective was to report new estimates about DALYs and death due to stroke attributed to smoking.

### **MATERIALS AND METHODS**

#### Data source

This study was conducted in accordance with the GBD Study 2021.<sup>[23,28,29]</sup> The GBD Study 2021 reported incidence, prevalence, DALYs, years lived with disability, years of life lost, and death for 371 diseases and injuries, along with estimates of healthy life expectancy.<sup>[29]</sup> These estimates were provided for sex and age groups in 204 countries and territories, including subnational estimates for 21 countries. Data sources used in the GBD Study 2021 included 100,983 data sources (19,189 new data sources for DALYs), 12 new causes, and other important methodological updates. More details about the data sources and methodology of the GBD Study 2021 were previously reported.<sup>[29]</sup> This research did not involve human or animal subjects, clinical trials, or sensitive personal data. Therefore, it falls outside the scope of studies requiring ethical clearance according to established guidelines.

#### **Case definitions**

Smoking was defined as tobacco smoking, chewing tobacco use, and second-hand smoke exposure.[30] Stroke was defined according to World Health Organization criteria as rapidly developing clinical signs of focal (or less commonly global) disturbance of cerebral function lasting more than 24 h or leading to death with no apparent cause other than that of vascular origin. Cases of transient ischemic attack were not included.<sup>[29]</sup> Ischemic stroke: (ICD-9 433-435.9, 437.0-437.1, 437.5-437.8) (ICD-10 G45-G46.8, I63-I63.9, I65-I66.9,I67.2-I67.3, I67.5-I67.6, I69.3) "characterized by occlusion of blood flow to part of the brain due to hypoperfusion, most commonly due to a thrombus or embolism. It is defined as an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction". Intracerebral hemorrhage: (ICD-9 431-432.9, 437.2) (ICD-10 I61-I62, I62.1-I62.9, I68.1-I68.2, I69.1-I69.2) "characterized by the rupture of a blood vessel resulting in bleeding into the intracerebral part of the brain. It is defined as focal collection of blood within the brain parenchyma or ventricular system that is not caused by trauma and results in a clinical stroke". Subarachnoid hemorrhage: (ICD-9 430-430.9) (ICD-10 I60-I60.9, I62.0, I67.0-I67.1, I69.0) "characterized as bleeding into the subarachnoid space (the space between the arachnoid membrane and the pia mater of the brain or spinal cord) resulting in a clinical stroke". Refer elsewhere for more details on GBD methodology.<sup>[29]</sup>

#### **Estimation framework**

Years lived with disability were estimated by multiplying prevalence estimates at varying levels of severity by an appropriate disability weight.<sup>[29]</sup> Years lived with disability were calculated by multiplying cause-specific deaths by the years of life expected to remain at death based on a normative life expectancy.<sup>[29]</sup> Disability-adjusted life years were calculated as the sum of years lived with disability and years of life lost.<sup>[29]</sup>

#### Statistical analysis

Analyses were conducted using Python version 3.10.4 (Python Software Foundation, Wilmington,

DE, USA), Stata version 13.1 (StataCorp, College Station, TX, USA), and R version 4.2.1 2 (R Foundation for Statistical Computing, Vienna, Austria). All ages and age-standardized estimates were calculated for prevalence, incidence, DALYs, and death due to stroke between 1990 and 2021.<sup>[31]</sup> In the GBD Study 2021, the relationship between 88 risk factors with selected health outcomes were estimated.<sup>[28]</sup> All age and agestandardized estimates of stroke attributed to smoking were calculated for DALYs and death between the years 1990 and 2021.<sup>[29]</sup> Estimates were based on per 100,000 individuals. A 95% uncertainty interval (UI) was reported for each of the reported estimates. More details about data, data processing, and modeling in the GBD Study 2021 were previously reported.<sup>[29]</sup> The GBD Study 2021 complied with the GATHER (Guidelines for Accurate and Transparent Health Estimates Reporting).<sup>[32]</sup>

						Ye	ear		
					1990			2021	
Measure	Cause	Location	Metric	Value	Lower	Upper	Value	Lower	Upper
Prevalence	] .	] ]		1,201.11	1,137.99	1,271.32	1,099.31	1,044.17	1,162.11
Incidence		Clabal		180.97	163.98	200.62	141.55	127.97	155.81
DALYs		Global		3,078.95	2,893.58	3,237.34	1,886.20	1,738.99	2,017.90
Deaths	Cr. 1.			144.31	133.86	152.04	87.45	78.92	94.14
Prevalence	Stroke	Í		1,097.12	996.5	1,203.13	934.35	860.27	1,015.71
Incidence		Tana		147.72	128.6	169.68	100.81	88.38	114.21
DALYs		Iran		2,470.21	2,277.04	2,673.16	1,229.18	1,119.52	1,332.60
Deaths	]			124.68	111.57	135.1	63.89	56.76	69.69
revalence	] .	]		899.17	795.73	1,001.64	784.92	710.53	863.92
ncidence	Ischemic	Ţ	Age-standardized	118.31	99.48	139.54	82.8	70.53	95.67
DALYs	stroke	Iran	rate	1,825.58	1,677.25	1,988.32	957.72	869.79	1,044.25
Deaths	]			99.79	89.3	108.93	52.97	47.06	57.9
Prevalence	] .	]		127.81	112.46	144.12	90.78	81.57	100.59
ncidence	Intracerebral	T.		22.53	19.24	25.79	13.25	11.46	15.05
DALYs	hemorrhage	Iran		540.41	480.36	594.2	230.56	210.89	251.65
Deaths				21.22	18.26	23.36	9.53	8.54	10.5
Prevalence	] .	1		73.61	65.53	82.82	61.11	54.85	67.86
ncidence	Subarachnoid	T		6.88	5.97	7.98	4.76	4.15	5.41
DALYs	hemorrhage	Iran		104.22	79.98	147.11	40.9	34.14	48.29
Deaths	]			3.66	2.34	5.5	1.4	1.05	1.69
DALYs	1	וו		121,405,471.72	114,722,212.95	127,625,131.78	160,457,220.63	147,781,420.22	171,642,573.58
revalence		01.1.1		50,415,602.15	47,793,499.16	53,227,185.77	93,816,414.10	89,030,218.63	99,335,466.96
ncidence		Global		7,019,116.45	6,345,597.43	7,794,216.33	11,946,273.94	10,772,079.55	13,219,841.45
Deaths	0.1		. 11 1	5,033,557.89	4,712,391.53	5,296,054.77	7,252,675.54	6,566,884.21	7,808,179.59
DALYs	Stroke		All ages number	639,836.09	592,990.09	693,488.82	904,630.42	828,258.53	981,197.99
revalence				383,202.59	349,215.94	417,620.25	787,178.55	726,667.84	855,320.19
ncidence		Iran		41,071.24	36,126.57	47,100.58	76,271.63	67,431.43	86,132.34
Deaths				22,960.12	21,033.05	24,840.13	41,908.22	37,515.95	45,630.12

#### RESULTS

#### Prevalence and death caused by stroke

The burden caused by stroke globally and in Iran was investigated, and the results are listed in Table 1. Age-standardized prevalence percent of stroke in 2021 was 1.14 (95% UI 1.09-1.21) globally and 0.98 (95% UI 0.90-1.06) in Iran (Supplementary Figure 1). Globally, 93,816,414 (95% UI 89,030,218-99,335,466) strokes were detected in 2021, and 787,178 (95% UI 726,667-855,320) cases of stroke were detected in Iran. The age-standardized prevalence rate of stroke per 100,000 individuals in 2021 was 1,099.31 (95% UI 1,044.17-1,162.11) globally and 934.35 (95% UI 860.27-1,015.71) in Iran. The age-standardized death rate of stroke per 100,000 individuals in 2021 was 87.45 (95% UI 78.92-94.14) globally and 63.89 (95% UI 56.76-69.69) in Iran. Age-standardized DALYs of stroke per 100,000 individuals in 2021 was 1,886.20 (95% UI 1,738.99-2,017.90) globally and 1,229.18 (95% UI 1,119.52-1,332.60) in Iran (Table 1). Although the prevalence, incidence, mortality, and disability rates of stroke globally and in Iran decreased between 1990 and 2021, the number of cases increased (Supplementary Figure 2).

## Burden of pathological types of stroke in Iran

The highest to lowest prevalence rates were ischemic stroke with 653,015.73 (95% UI 591. 272.44-718,460.97), intracerebral hemorrhage with 81,265.68 (95% UI 72,921.41-90.120.11). and subarachnoid hemorrhage with 54,855.13 (95% UI 49,044.16-61,208.86). Ischemic stroke had the highest death rate with 34,027.27 (95% 30,355.10-37,131.72), followed by intracerebral hemorrhage (6,875.13 [95% UI 6,192.56-7,539.64]) and subarachnoid hemorrhage (1,005.82 [95% UI 786.71-1,212.57]; Supplementary Figure 3).

## Burden of stroke stratified by males and females in Iran

Age-standardized prevalence ratio per 100,000 individuals in 2021 was higher in males (1,011.98 [95% UI 925.92-1,105.32]) than in females (856.98 [95% UI 792.85-928.94]). Age-standardized DALYs per 100,000 individuals in 2021 was higher in males (1,274.02 [95% UI 1,162.97-1,398.27]) than in females (1,190.38 [95% UI 1,058.47-1,307.77]). However, age-standardized death rate per 100,000 in 2021 was higher in females (66.18 [95% UI 56.4674.20]) than in males (62.37 [95% UI 55.68-68.74]; Table 2, Supplementary Figure 4).

#### Stroke burden stratified by provinces

The highest age-standardized prevalence rate of stroke per 100,000 individuals was in Bushehr (1,203.06 [95% UI 1,099.39-1,312.52]), and the lowest was in Tehran (809.91 [95% UI 740.53-879.40]). The highest age-standardized DALYs of stroke per 100,000 individuals was in Golestan (1,747.00 [95% UI 1,539.88-1,943.83]), and the lowest was in Tehran (847.70 [95% UI 721.41-985.51]). The highest age-standardized death rate of stroke per 100,000 individuals was in Golestan (85.59 [95% UI 74.89-95.69]), and the lowest was in Tehran (44.67 [95% UI 36.71-52.81]; Table 3 Figure 1).

#### Stroke burden stratified by age in Iran

The highest age-standardized prevalence rate of stroke per 100,000 individuals was detected in those aged 55 years or older (3,171.30 [95% UI 2,824.99-3,512.51]), and the lowest was detected in those aged 15 to 19 years (228.55 [95% UI 197.74-265.27]). The highest age-standardized DALYs rate of stroke per 100,000 individuals was in those aged 55 years or older (5,268.44 [95% UI 4,798.71-5,719.31]), and the lowest was in those aged 15 to 19 years (134.79 [95% UI 117.79-150.88]). More than 90% of all stroke deaths occured in those aged 55 years or older (38,308.07 [95% UI 34,084.10-41,826.74]; Table 4).

#### Stroke attributed to smoking

Age-standardized DALYs of stroke attributed to smoking per 100,000 individuals was 328.94 [95% UI 270.32-393.11] globally and 141.75 [95% UI 112.46-173.37] in Iran. The global age-standardized death from stroke attributed to smoking per 100,000 individuals was 12.65 [95% UI 10.09-15.55], with 5.40 [95% UI 4.18-6.81] in Iran. More than one million cases of death have been attributed to tobacco use in the world (1,077,804 [95% UI 865,541-1,320,753]), with 4,007 [95% UI 3,159-4,972] in Iran. Compared to 1990, there was an increase in the number of deaths caused by tobacco use (0.20 [95% UI 0.06-0.35]), and this growth was higher in Iran (0.52 [95% UI 0.31-0.79]; Table 5; Figure 2).

#### Stroke attributed to smoking stratified by sex

Age-standardized DALYs of stroke attributed to smoking per 100,000 individuals was 218.97

#### TABLE 2 Year 1990 2021 Value Measure Cause Sex Lower Upper Value Lower Upper Males 2,476.36 2,236.46 1,274.02 1,162.97 2,718.37 1,398.27 DALYs (Disability-Adjusted Life Years) Females 2,441.59 2,137.34 2,712.03 1,190.38 1,058.47 1,307.77 Males 1,097.47 989.15 1,204.83 1,011.98 925.92 1,105.32 Prevalence 1,100.22 1,207.26 856.98 928.94 Females 1,002.60 792.85 Stroke Males 151.24 130.63 175.81 107.05 93.85 121.23 Incidence Females 143.1 162.12 95.03 107.49 125.29 83.64 Males 121.32 107.5 133.22 62.37 55.68 68.74 Deaths Females 126.52 108.52 140.37 66.18 56.46 74.2 1,976.63 876.62 1,070.08 Males 1,794.10 1,608.83 972.53 DALYs (Disability-Adjusted Life Years) Females 1,840.00 1,611.26 2,070.62 949.02 841.2 1,044.06 Males 903.25 798.03 1,005.26 860.95 776 951.01 Prevalence Females 898.44 801.37 1,002.12 709.23 642.74 778.53 Ischemic stroke Males 119.75 100.04 143.87 87.66 74.69 102.1 Incidence Females 115.81 97.85 134.53 78.43 67.06 90.53 Males 95.37 105.13 45.12 56.04 84.27 50.93 Deaths Females 102.93 115.45 55.72 47.74 62.35 87.78 Males 580.76 497.32 660.82 262.44 240.07 286.26 DALYs (Disability-Adjusted Life Years) Females 576.52 174.56 222.7 494.87 423.71 198.57 Males 135.8 119.37 152.82 102.02 91.77 113.17 Prevalence Females 119.3 104.81 134.63 79.36 71.14 88.1 Intracerebral hemorrhage Males 24.81 21.05 28.55 14.85 12.84 16.92 Incidence Females 20.18 17.16 23.01 11.62 9.94 13.29 Males 22.27 18.65 25.39 11.16 10.149.14 Deaths Females 19.96 16.59 23.41 8.96 7.71 10.26 101.51 57.94 154.51 29.87 50.44 Males 39.05 DALYs (Disability-Adjusted Life Years) Females 106.72 147.01 35.07 51.96 72.36 42.79 Males 61.96 54.88 69.81 51.85 46.35 57.94 Prevalence 96.27 Females 85.88 76.56 70.46 63.21 78 18 Subarachnoid hemorrhage Males 6.68 5.76 7.74 4.54 3.95 5.16 Incidence Females 7.12 6.15 8.23 4.98 4.31 5.69 0.88 Males 3.68 1.7 6.02 1.741.3 Deaths Females 3.63 2.22 5.59 1.5 1.09 1.83

DALYs: Disability-adjusted life years.

[95% UI 176.33-265.12] in males and 64.77 [95% UI 45.87-84.77] in females. Number of DALYs of stroke attributed to smoking was 93,526 [95% UI 75,896-112,357] in males and 26,886 [95% UI 19,240-34,988] in females.

Age-standardized death from stroke attributed to smoking per 100,000 individuals was 8.18 [95%

UI 6.42-10.23] in males and 2.63 [95% UI 1.77-3.55] in females. Almost a quarter of deaths attributed to tobacco use in Iran were in males (3,084 [95% UI 2,469-3,784]) compared with females (922 [95% UI 636-1,223]). This finding suggests that the burden of stroke attributable to smoking was much higher in males than in females (Table 6; Supplementary Figure 5).

Age-standardized pre	T. valence, incidence, DALY, and d	<b>ABLE 3</b> eath in Ira	n stratified	by provinc	es <u>betwee</u> r	n 19 <u>90 and</u>	2021
inge standardized pre	valence, meldence, bribi, and d		n otratifica	••	ear	17770 and	2021
			1990			2021	
Measure	Location	Value	Lower	Upper	Value	Lower	Upper
	Alborz	2,484.56	2,113.63	2,857.66	1,236.43	1,045.28	1,442.04
	Ardebil	2,360.40	2,004.63	2,770.78	1,421.11	1,230.02	1,646.23
	Bushehr	2,882.13	2,456.37	3,350.32	1,564.45	1,351.40	1,790.51
	Chahar Mahaal and Bakhtiari	2,211.61	1,905.32	2,522.75	1,026.65	883.67	1,203.86
	East Azerbaijan	2,791.95	2,411.78	3,207.67	1,394.90	1,186.62	1,679.06
	Fars	2,571.83	2,219.87	3,006.69	1,419.29	1,219.21	1,642.73
	Gilan	2,877.06	2,447.39	3,284.93	1,496.35	1,308.99	1,693.41
	Golestan	2,897.08	2,472.59	3,361.80	1,747.00	1,539.88	1,943.83
	Hamadan	2,747.33	2,306.45	3,203.57	1,323.64	1,150.05	1,509.57
	Hormozgan	2,990.42	2,557.35	3,496.88	1,372.14	1,170.84	1,584.47
	Ilam	1,949.65	1,677.67	2,230.37	1,144.93	984.98	1,311.49
	Isfahan	1,965.27	1,655.08	2,345.85	1,032.55	882.01	1,186.57
	Kerman	2,480.42	2,122.37	2,845.76	1,252.68	1,054.49	1,444.86
	Kermanshah	3,328.11	2,806.08	3,815.43	1,497.28	1,284.77	1,722.22
	Khorasan-e-Razavi	2,988.14	2,528.68	3,486.25	1,381.61	1,186.08	1,587.82
DALYs	Khuzestan	2,784.05	2,395.14	3,221.00	1,569.18	1,373.20	1,776.91
	Kohgiluyeh and Boyer-Ahmad	2,236.25	1,885.39	2,601.45	1,162.13	998.52	1,337.36
	Kurdistan	2,862.82	2,483.47	3,318.93	1,213.26	1,026.37	1,403.89
	Lorestan	2,815.57	2,405.38	3,217.58	1,351.42	1,149.71	1,555.75
	Markazi	2,753.47	2,361.90	3,174.43	1,094.01	920.66	1,278.56
	Mazandaran	2,190.89	1,833.92	2,559.67	1,225.66	1,052.40	1,421.51
	North Khorasan	2,875.07	2,419.80	3,397.71	1,384.41	1,187.66	1,621.48
	Qazvin	2,448.95	2,093.63	2,816.54	1,334.46	1,157.12	1,521.49
	Qom	2,816.26	2,384.61	3,244.44	1,142.34	974.52	1,306.23
	Semnan	2,573.82	2,235.11	2,954.84	1,159.33	990.89	1,331.30
	Sistan and Baluchistan	2,571.74	2,169.16	2,956.61	1,440.06	1,208.71	1,689.91
	South Khorasan	1,919.64	1,653.58	2,219.78	975.03	849.58	1,114.71
	Tehran	1,630.64	1,340.55	1,961.93	847.7	721.41	985.51
	West Azerbaijan	2,802.62	2,430.41	3,247.09	1,495.42	1,305.15	1,745.70
	Yazd	2,754.47	2,346.71	3,153.43	1,228.09	1,046.57	1,416.23
	Zanjan	2,301.72	1,953.52	2,656.59	1,223.51	1,077.78	1,396.33
	Alborz	1,175.38	1,055.59	1,288.44	999.95	916.85	1,089.39
	Ardebil	1,098.87	976.45	1,207.52	1,024.76	939.83	1,127.25
	Bushehr	1,325.46	1,199.65	1,459.91	1,203.06	1,099.39	1,312.52
	Chahar Mahaal and Bakhtiari	1,089.38	983.01	1,199.23	933.58	847.28	1,024.29
	East Azerbaijan	1,120.32	1,015.20	1,239.87	943.86	861.79	1,031.31
	Fars	1,071.25	965.32	1,180.35	995.48	905.01	1,096.27
Prevalence	Gilan	1,211.99	1,094.13	1,319.61	1,050.71	956.96	1,156.85
	Golestan	1,231.08	1,105.02	1,365.36	1,129.74	1,016.62	1,241.16
	Hamadan	1,115.58	1,001.30	1,232.04	1,000.21	913.5	1,094.05
	Hormozgan	1,182.14	1,057.01	1,306.94	991.84	906.05	1,084.22
	Ilam	906.04	818.7	1,000.33	826.48	757.28	908.5
	Isfahan	1,006.78	912.6	1,106.36	816.25	743.58	892.36
	Kerman	1,013.72	913.36	1,128.01	844.59	766.29	929.41

		ABLE 3 ontinued					
				Ye	ear		
			1990			2021	
Measure	Location	Value	Lower	Upper	Value	Lower	Upper
	Kermanshah	1,189.42	1,066.32	1,326.28	999.11	911.65	1,086.26
	Khorasan-e-Razavi	1,123.55	1,013.33	1,240.65	919.98	838.7	1,006.91
	Khuzestan	1,232.73	1,110.90	1,365.69	1,172.89	1,056.86	1,294.76
	Kohgiluyeh and Boyer-Ahmad	1,094.17	990.05	1,210.08	979.89	893.75	1,070.61
	Kurdistan	1,073.39	969.12	1,187.43	884.02	804.87	966.48
	Lorestan	1,127.27	1,013.91	1,244.48	962.59	876.76	1,059.42
	Markazi	1,170.99	1,065.75	1,285.14	940.35	862.3	1,028.36
	Mazandaran	1,197.20	1,081.62	1,321.82	1,040.49	950.22	1,133.70
D 1	North Khorasan	1,119.65	1,000.81	1,227.62	987.97	897.58	1,080.45
Prevalence	Qazvin	959.29	865.46	1,056.07	864.24	793.37	950.6
	Qom	1,127.20	1,031.10	1,241.58	813.84	743.21	882.43
	Semnan	1,179.19	1,066.39	1,310.62	992.8	899.14	1,088.60
	Sistan and Baluchistan	953.3	859.05	1,052.82	918.6	840.99	1,003.21
	South Khorasan	957.99	868.15	1,057.87	840.24	770.23	920.76
	Tehran	1,007.43	909.06	1,110.17	809.91	740.53	879.4
	West Azerbaijan	1,071.43	967.79	1,176.72	928.92	849.04	1,020.21
	Yazd	1,072.68	972.89	1,175.54	921.49	839.55	1,007.55
	Zanjan	1,081.18	979.51	1,185.45	896.78	817.04	974.82
	Alborz	152.31	132.79	173.72	105.66	92.66	120.1
	Ardebil	147.75	128.74	169.24	114.18	99.59	130.14
	Bushehr	167.2	144.67	193.86	129.52	112.76	147.46
	Chahar Mahaal and Bakhtiari	146.4	126.73	170.08	100.73	88.18	114.44
	East Azerbaijan	153.97	134.57	175.49	107.38	94.48	121.27
	Fars	149.39	128.75	172.51	111.74	97.91	126.06
	Gilan	163.11	141.96	185.14	116.09	102.37	131.28
	Golestan	159.94	138.97	184.95	123.27	106.73	139.32
	Hamadan	147.91	130.03	170.79	109.61	96.28	125.54
	Hormozgan	158.21	136.77	183.3	107.61	94.66	122.38
	Ilam	126.34	110.28	145.87	94.25	82.37	106.78
	Isfahan	138.19	119.04	159.06	87.63	76.53	98.81
Incidence	Kerman	132.95	115.94	153.28	96.4	84.55	109.32
	Kermanshah	166.7	144.73	192.04	112.16	98.6	126.85
	Khorasan-e-Razavi	162.72	141.75	186.24	105.51	92.82	118.6
	Khuzestan	160.24	138.07	185.48	123.16	107.36	139.69
	Kohgiluyeh and Boyer-Ahmad	148	130.64	169.39	102.13	90.13	115.81
	Kurdistan	153.02	134.15	175.26	98.58	87.17	110.38
	Lorestan	157.59	137.89	180.49	109.36	96.07	123.6
	Markazi	159.2	138.22	183.44	101.71	89.31	115.68
	Mazandaran	153.4	132.54	175.89	109.82	96.77	123.41
	North Khorasan	156.37	132.94 135.61	180.67	109.82	90.77 95.5	123.41
	Qazvin	137.46	120.15	156.95	102.37	91.16	114.96
	Qazvin Qom	161.23	139.57	130.93 185.56	93.83	82.88	106.7
					95.85 106.83		
	Semnan	150.71	130.2	175.39	100.85	93.33	122.63

		ABLE 3 ontinued					
				Ye	ar		
			1990			2021	
Measure	Location	Value	Lower	Upper	Value	Lower	Upper
	Sistan and Baluchistan	137.02	120.88	157.64	102.03	91.07	115.99
	South Khorasan	138.25	119.86	160.48	95.39	83.94	108.05
	Tehran	127.04	110.23	145.66	79.02	68.68	90.13
Incidence	West Azerbaijan	147.49	128.87	169.06	109.4	96.06	123.38
	Yazd	149.3	129.25	171.09	104.35	91.96	118.25
	Zanjan	143.53	125.56	163.84	101.83	89.14	115.31
	Alborz	134.06	113.41	154.97	67.88	56.45	79.79
	Ardebil	112.18	93.4	130.89	72.02	61.27	84.5
	Bushehr	149.41	125.61	170.3	83.01	70.65	95.15
	Chahar Mahaal and Bakhtiari	108.15	92.17	122.63	52.94	44.68	62.72
	East Azerbaijan	153.34	132.09	175.58	80.11	68.07	96.6
	Fars	134.6	114.86	154.49	77.81	65.23	90.26
	Gilan	149.25	125.4	170.38	79.98	68.54	91.2
	Golestan	137.42	116.24	158.03	85.59	74.89	95.69
	Hamadan	130.31	107.59	152.53	63.85	53.71	73.34
	Hormozgan	142.88	122.94	166.06	69.95	59.02	80.8
	Ilam	96.07	82.7	110.17	61.48	52.19	70.27
	Isfahan	103.75	85.66	123.43	55.19	45.35	64.19
	Kerman	125.55	107.54	142.41	67.34	56.6	78.02
	Kermanshah	162.7	138.44	185.15	77.89	65.52	90.01
	Khorasan-e-Razavi	150.43	128.67	173.85	72.35	60.6	84.54
Deaths	Khuzestan	140.3	120.09	160.5	79.33	68.04	91.33
	Kohgiluyeh and Boyer-Ahmad	106.14	88.85	124.47	56.26	47.02	65.98
	Kurdistan	136.89	118.35	157.05	61.96	50.86	72.52
	Lorestan	136.87	116.64	156.19	68.51	57.05	78.98
	Markazi	138.95	118.91	159.5	55.29	45.69	65.22
	Mazandaran	111.23	91.35	130.44	61.47	51.21	72.53
	North Khorasan	137.79	115.56	162.83	67.33	56.72	79.73
	Qazvin	122.38	103.32	140.77	71.71	61.24	82.45
	Qom	149.33	126.03	172.58	61.97	51.98	71.28
	Semnan	130.44	112.68	149.11	62.77	52.04	72.83
	Sistan and Baluchistan	122.81	102.78	140.59	62.11	50.93	73.65
	South Khorasan	95.4	80.33	111.72	49.75	42.07	57.84
	Tehran	81.81	66.59	98.31	44.67	36.71	52.81
	West Azerbaijan	149.84	128.05	170.93	85.53	73.38	100.39
	Yazd	147.71	124.27	167.29	69.07	57.54	80.28
	Zanjan	111.6	94.67	129.48	64.79	55.13	74.38

# Stroke attributed to smoking stratified by provinces

The highest age-standardized DALYs attributed to smoking per 100,000 individuals was in Golestan

(207.43 [95% UI 162.20-264.40]), and the lowest was in Tehran (99.95 [95% UI 75.87-131.30]). The highest age-standardized death rate attributed to smoking per 100,000 individuals was in Golestan (7.53 [95% UI 5.79-9.79]), and the lowest was in



**Figure 1. (a)** Age-standardized prevalence rate of stroke per 100,000 individuals. **(b)** Age-standardized DALYs of stroke per 100,000 individuals. **(c)** Age-standardized death rate of stroke per 100,000 individuals. DALYs: Disability-adjusted life years.

1	68
	00

15-19 years       319.88       274.54       374.41       228.55       197.74       25.27         20-24 years       422.95       365.75       487.51       316.99       277.2       359.81         25-29 years       537.45       466.81       615.03       413.57       363.86       470.8         30-34 years       67.177       582.44       767.4       520.36       456.85       587.55         35-39 years       846.8       730.36       962.92       655.41       576.85       735.2         40-44 years       1.086.23       942.12       1.235.76       842.24       744.9       94.41         15-19 years       2.172.93       1.652.30       1.141.59       100.62.2       1.280.00         55 + years       3.428.57       2.979.82       3.885.10       3.171.30       2.821.99       3.512.51         1cidence       25.39 years       52.22       70.55       40.73       2.15.2       15.27       29.1         30.34 years       82.59       60.58       106.73       53.53       39.94       68.51         45-49 years       127.28       87.62       172.4			TABLE 4					
Measure       Age       Value       Lower       Upper       Value       Lower       Upper         15-19 years       319.88       274.54       374.41       228.55       316.99       27.72       359.81         20-24 years       43.2295       365.55       447.51       316.99       27.72       359.81         25-29 years       537.45       466.81       615.03       413.37       456.86       567.55         30-34 years       67.177       582.64       767.4       520.36       645.85       587.55         40-44 years       1,086.23       942.12       1,255.76       842.24       744.9       944.71         45-49 years       1,272.93       1,652.30       1,41.59       1,06.22       1,280.09         515-19 years       3,225.7       1,57.5       5,35       20.3       149.49       27.93         15-19 years       22       15,34       32.98       17.9       1,23.3       26.3         20-24 years       3,22.57       10.73       2,15.2       15.27       29.1         30-34 years       53.22       37.05       7,5.3       5.35       20.	Age-standardized			Iran stratif	ied by age	between 1	990 and 20	)21
Measure       Age       Value       Lower       Upper       Value       Lower       Upper         15-19 years       39288       27454       37441       22855       19774       26527         20-24 years       35295       36575       34651       31699       277.2       359281         20-24 years       57355       46681       61503       41337       363.86       470.8         30-34 years       671.77       582.64       767.4       520.36       456.85       587.55         35-39 years       1,460.25       1,272.95       1,652.30       1,1159       1,006.22       1,280.00         50-54 years       1,973.22       1,685.57       2,259.00       1,557.96       1,357.34       1,754.02         55+ years       3,288.7       2,979.82       3,888.10       3,171.30       2,824.99       3,512.51         16:dence       35-39 years       53.22       37.05       75.93       3,518       2,47.3       50.48         10:cidence       35-39 years       53.22       37.05       75.93       3,518       2,47.3       50.48         10:cidence       35-39					Ye	ear		
15-19 years       319.88       274.54       374.41       228.55       197.74       25.27         20-24 years       422.95       365.75       487.51       316.99       277.2       359.81         25-29 years       537.45       466.81       615.03       413.57       363.86       470.8         30-34 years       67.177       582.44       767.4       520.36       456.85       587.55         35-39 years       846.8       730.36       962.92       655.41       576.85       735.2         40-44 years       1.086.23       942.12       1.235.76       842.24       744.9       94.41         15-19 years       2.172.93       1.652.30       1.141.59       100.62.2       1.280.00         55 + years       3.428.57       2.979.82       3.885.10       3.171.30       2.821.99       3.512.51         1cidence       25.39 years       52.22       70.55       40.73       2.15.2       15.27       29.1         30.34 years       82.59       60.58       106.73       53.53       39.94       68.51         45-49 years       127.28       87.62       172.4								
Prevalence       20-24 years       422.95       365.75       487.51       316.99       277.2       359.81         25-29 years       537.45       466.81       051.03       413.37       365.86       470.8         30-34 years       671.77       582.64       767.4       520.6       456.85       785.5         40-44 years       1,086.23       942.12       1,235.76       842.24       744.9       944.71         45-49 years       1,063.51       1,272.93       1,653.50       1,575.0       1,357.34       1,754.02         55+ years       3,428.57       2,279.82       3,885.10       3,171.30       2,824.99       3,512.51         16:49 years       22       15.34       32.98       179       12.33       2.6.3         20-24 years       25.77       18.75       352.5       2.0.57       14.94       2.72       2.9.1       3.0.43       3.11       3.0.42       1.9.2       1.5.27       2.9.1         1ncidence       15-19 years       28.2       37.05       7.5.93       3.5.18       2.47.7       2.64.5       1.9.81       3.5.11         30-34 years       1	Measure							
Prevalence       25-29 years       557.45       466.81       615.03       413.37       363.86       470.8         30-34 years       671.77       582.64       767.4       520.36       456.85       587.55         35-39 years       846.8       730.36       962.92       654.1       576.85       735.2         40-44 years       1,066.23       942.12       1,252.30       1,141.59       1,006.22       1,220.00         50-54 years       1,973.22       1,685.57       2,259.00       1,557.96       1,357.34       1,754.02         55+ years       3,428.57       2,979.82       3,885.10       3,171.30       2,824.99       3,512.51         1ncidence       15-19 years       22       15.34       32.98       179       12.33       26.3         20-24 years       25.57       18.75       35.25       20.3       149.44       279.3         25-29 years       20.27       20.55       40.75       24.52       15.27       29.1         30-34 years       52.22       50.57       26.53       19.81       35.11         35-14       54.49 years       127.28 <td< td=""><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td></td<>		-						
30-34 years       671.77       582.64       767.4       520.36       456.85       58755         35-39 years       846.8       730.36       962.92       655.41       576.85       735.2         40-44 years       1.086.23       942.12       1.235.76       842.42       744.9       944.71         45-49 years       1.733.22       1.655.57       2.5290       1.575.96       1.573.41       1.574.02       1.280.00         50-54 years       3.428.57       2.979.82       3.885.10       3.171.30       2.824.99       3.512.51         20-24 years       25.57       18.75       35.25       20.3       144.4       2793         20-24 years       25.57       18.75       35.12       30.3       14.94       2793         30-34 years       38.47       29.2       50.57       26.45       19.81       35.11         35-39 years       53.22       37.05       75.93       35.18       24.73       50.48         45-49 years       127.28       87.62       172.24       82.16       60.55       108.29         50-54 years       127.28       87.65       704.73		-						
Prevalence     35-39 years     846.8     730.36     962.92     655.41     57.65     735.2       40-44 years     1,086.23     942.12     1,235.76     842.24     744.9     944.71       45-49 years     1,060.55     1,272.93     1,652.30     1,141.99     1,006.22     1,280.00       50-54 years     3,428.57     2,379.82     3,885.10     3,171.30     2,824.99     3,512.51       15-19 years     22     15.34     32.98     179     1,23.3     26.3       20-24 years     25.57     18.75     35.25     20.3     14.94     27.93       25-29 years     30-34 years     88.47     20.2     50.57     26.45     19.81     35.11       30-34 years     88.47     20.2     50.57     26.45     19.81     35.18     24.73     50.48       30-34 years     82.59     60.58     106.73     35.35     39.94     68.51       40-44 years     82.59     60.58     106.73     53.53     39.94     68.51       45-49 years     20.57     26.46     173.44     152.99     19.32.6     25.49     1								
40-44 years     1,086.23     942.12     1,235.76     842.24     744.9     944.71       45-49 years     1,460.35     1,272.93     1,652.30     1,141.59     1,060.22     1,280.00       50-54 years     1,973.22     1,685.57     2,259.90     1,557.66     1,357.34     1,754.02       51-9 years     2,297.82     3,851.01     3,171.30     2,824.99     3,512.51       20-24 years     25.57     18.75     35.25     20.3     14.94     279.32       25-29 years     29.27     20.55     40.73     21.52     15.77     29.1       30-34 years     53.22     37.05     75.93     3,18     24.73     50.48       40-44 years     127.28     87.62     172.24     82.16     60.55     108.29       50-54 years     127.28     87.62     172.24     82.16     60.55     108.29       55-9 years     206.15     179.49     23.19     134.79     117.79     150.88       40-44 years     1,244.23     1,71.4     152.93     193.26     252.94     117.95     91.37     147.09       55+ years     2								
45-49 years     1,460.35     1,272.93     1,652.30     1,141.9     1,006.22     1,280.00       50-54 years     1,973.22     1,685.57     2,259.90     1,557.96     1,357.34     1,754.02       55+ years     3,428.57     2,979.82     3,885.10     3,171.30     2,824.99     3,512.51       15-19 years     22     15.34     32.98     179     12.33     26.3       20-24 years     25.57     18.75     35.25     20.3     14.94     2793       30-34 years     38.47     20.2     50.57     26.45     19.81     35.11       35-39 years     35.22     37.05     750.33     351.8     24.73     50.48       40-44 years     82.59     60.58     106.73     53.53     39.94     668.51       45-49 years     127.28     87.62     172.24     82.16     60.55     108.29       50-54 years     185.27     137.95     232.89     117.95     91.37     147.09       55+ years     204.15     179.49     233.19     134.79     117.79     150.88       20-24 years     20.615     179.49	Prevalence							
50-54 years       1,973.22       1,685.57       2,259.90       1,557.96       1,357.34       1,754.02         55+ years       3,428.57       2,979.82       3,885.10       3,171.30       2,824.99       3,512.51         15-19 years       22       15.34       32.98       179       12.33       26.3         20-24 years       29.27       20.55       40.73       21.52       15.27       29.1         30-34 years       38.47       29.2       50.57       26.45       19.81       35.11         35-39 years       53.22       37.05       75.93       35.18       24.73       50.48         40-44 years       82.59       60.58       106.73       53.53       39.94       66.51         45-49 years       127.28       87.62       172.24       82.16       60.55       108.29         50-54 years       479.33       387.33       592.34       390.15       327.53       458.62         15-19 years       206.15       179.49       23.19       134.79       117.99       15.88         20-24 years       240.47       264.46       173.44       152.93 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>								
55+ years       3,428,57       2,979,82       3,885,10       3,171,30       2,824,99       3,512,51         15-19 years       22       15,34       32,98       17.9       12,33       26,3         20-24 years       25,57       18,75       35,25       20,3       14,94       2793         30-34 years       38,47       29.2       20,55       20,57       26,45       19,81       35,51         30-34 years       35,22       3705       75,93       35,18       24,73       50,48         40-44 years       82,59       60,58       106,73       53,53       39,94       68,51         45-49 years       127,28       87,62       172,24       82,16       60,55       108,29         50-54 years       185,27       137,95       232,89       117,95       91,37       147,09         55 + years       479,33       387,33       592,34       300,15       327,53       458,62         15-19 years       206,15       179,49       233,19       134,79       117,79       150,88         20-24 years       206,15       179,49       233,19       134,79		-	1,460.35					
Incidence       15-19 years       22       15.34       32.98       179       12.33       26.3         20-24 years       25.57       18.75       35.25       20.3       14.94       27.93         25-29 years       29.27       20.55       40.73       21.52       15.27       29.1         30-34 years       38.47       29.2       50.57       26.45       19.81       35.11         35-39 years       53.22       37.05       75.93       35.18       24.73       50.48         40-44 years       82.59       60.58       106.73       53.53       39.94       66.81         45-49 years       127.28       87.62       172.24       82.16       60.55       108.29         50-54 years       185.27       137.95       232.89       117.95       91.37       147.09         55+ years       20-24 years       234.78       204.77       264.46       173.44       152.93       193.26         25-29 years       306.77       265.03       355.75       201.07       178.35       224.01         30-34 years       1,014.17       909.7       1,137.33								
DALYS       20-24 years       25.57       18.75       35.25       20.3       14.94       27.93         1ncidence       25-29 years       29.27       20.55       40.73       21.52       15.27       29.1         30-34 years       38.47       29.2       50.57       26.45       19.81       35.11         35-39 years       53.22       37.05       75.93       35.18       24.73       50.48         40-44 years       82.59       60.58       106.73       53.53       39.94       68.51         45-49 years       127.28       87.62       172.24       82.16       60.55       108.29         50-54 years       185.27       137.95       232.89       117.95       91.37       147.09         20-24 years       244.78       204.77       264.46       173.44       152.93       193.26         25-29 years       306.77       265.03       355.75       20.107       178.35       22.401         30-34 years       1,014.17       909.7       1,137.3       486.7       348.9       532.05         40-44 years       1,014.17       909.7       1,137.3 <td></td> <td>55+ years</td> <td>3,428.57</td> <td>2,979.82</td> <td>3,885.10</td> <td>3,171.30</td> <td>2,824.99</td> <td>3,512.51</td>		55+ years	3,428.57	2,979.82	3,885.10	3,171.30	2,824.99	3,512.51
1       25-29 years       29.27       20.55       40.73       21.52       15.27       29.1         30-34 years       38.47       29.2       50.57       26.45       19.81       35.11         35-39 years       53.22       37.05       75.93       35.18       24.73       50.48         40-44 years       82.59       60.58       106.73       53.53       39.94       68.51         45-49 years       127.28       87.62       172.24       82.16       60.55       108.29         50-54 years       185.27       137.95       232.89       117.95       91.37       147.09         55+ years       479.33       387.33       592.34       30.15       327.53       458.62         15-19 years       206.15       179.49       233.19       134.79       175.98       20.24       193.26       25.24       20.107       178.35       22.0107       178.35       22.0107       178.35       22.0107       178.35       22.0107       178.35       22.0107       178.35       22.0107       178.35       22.0107       178.35       22.0107       174.23       35.25       45.41		15-19 years	22	15.34	32.98	17.9	12.33	26.3
Jncidence       30-34 years       38.47       29.2       50.57       26.45       19.81       35.11         Jncidence       35-39 years       53.22       37.05       75.93       35.18       24.73       50.48         40-44 years       82.59       60.58       106.73       53.53       39.94       68.51         45-49 years       127.28       87.62       172.24       82.16       60.55       108.29         50-54 years       185.27       137.95       232.89       117.95       91.37       147.09         55+ years       479.33       387.33       592.34       390.15       327.53       458.62         0       74       264.16       173.44       152.93       193.26         25-29 years       306.77       264.46       173.44       152.93       193.26         25-29 years       366.77       264.46       173.44       152.93       193.26         35-39 years       620       548.65       704.73       330.63       293.66       365.3         40-44 years       1,014.17       90.7       1,137.33       485.77       438.9       532.05		20-24 years	25.57	18.75	35.25	20.3	14.94	27.93
Incidence       35-39 years       53.22       37.05       75.93       35.18       24.73       50.48         40-44 years       82.59       60.58       106.73       53.53       39.94       68.51         45-49 years       127.28       87.62       172.24       82.16       60.55       108.29         50-54 years       185.27       137.95       232.89       117.95       91.37       147.09         55+ years       479.33       387.33       592.34       390.15       327.53       458.62         70-24 years       234.78       204.77       264.46       173.44       152.93       193.26         25-29 years       306.77       265.03       355.75       201.07       178.35       224.01         30-34 years       411.32       356.56       469.27       244.23       217.74       271.39         35-39 years       620       548.65       704.73       330.63       293.66       365.3         40-44 years       1,014.17       909.7       1,137.33       485.77       438.9       532.05         45-49 years       2,66       2.8       2,52.695       <		25-29 years	29.27	20.55	40.73	21.52	15.27	29.1
40-44 years       82.59       60.58       106.73       53.53       39.94       68.51         45-49 years       127.28       87.62       172.24       82.16       60.55       108.29         50-54 years       185.27       137.95       232.89       117.95       91.37       147.09         55+ years       479.33       387.33       592.34       390.15       327.53       458.62         0.54       years       234.78       204.77       264.46       173.44       152.93       193.26         25-29 years       306.77       265.03       355.75       201.07       178.35       224.01         30-34 years       411.32       356.56       469.27       244.23       217.74       271.39         35-39 years       620       548.65       704.73       330.63       293.66       365.3         40-44 years       1,014.17       909.7       1,137.33       485.77       438.9       532.05         45-49 years       2,766.38       2,526.95       3,071.06       1,192.22       1,082.11       1,304.70         5-9       years       2.66       2.23		30-34 years	38.47	29.2	50.57	26.45	19.81	35.11
45-49 years     127.28     87.62     172.24     82.16     60.55     108.29       50-54 years     185.27     137.95     232.89     117.95     91.37     147.09       55+ years     479.33     387.33     592.34     390.15     327.53     458.62       70-24 years     206.15     179.49     233.19     134.79     117.79     150.88       20-24 years     234.78     204.77     264.46     173.44     152.93     193.26       25-29 years     306.77     265.03     355.75     201.07     178.35     224.01       30-34 years     411.32     356.56     469.27     244.23     217.74     271.39       35-39 years     620     548.65     704.73     330.63     293.66     365.3       40-44 years     1,014.17     909.7     1,137.33     485.77     438.9     532.05       45-49 years     2,66.38     2,526.95     3,071.06     1,92.22     1,082.11     1,304.70       55+ years     8,872.68     8,173.38     9,582.98     5,268.44     4,798.71     5,719.31       0-24 years     2.6	Incidence	35-39 years	53.22	37.05	75.93	35.18	24.73	50.48
50-54 years     185.27     137.95     232.89     117.95     91.37     147.09       55+ years     479.33     387.33     592.34     390.15     327.53     458.62       15-19 years     206.15     179.49     233.19     134.79     117.79     150.88       20-24 years     234.78     204.77     264.46     173.44     152.93     193.26       25-29 years     306.77     265.03     355.75     201.07     178.35     224.01       30-34 years     411.32     356.56     469.27     244.23     217.74     271.39       35-39 years     620     548.65     704.73     330.63     293.66     365.3       40-44 years     1,014.17     909.7     1,137.33     485.77     438.9     532.05       45-49 years     2,766.38     2,526.95     3,071.06     1,92.22     1,082.11     1,304.70       55+ years     8,872.68     8,173.38     9,582.98     5,268.44     4,798.71     5,719.31       0     54-49 years     2,66     2.23     2.95     1.91     1.68     2.16       20-24 years     2,6		40-44 years	82.59	60.58	106.73	53.53	39.94	68.51
55+ years     479.33     387.33     592.34     390.15     327.53     458.62       15-19 years     206.15     179.49     233.19     134.79     117.79     150.88       20-24 years     234.78     204.77     264.46     173.44     152.93     193.26       25-29 years     306.77     265.03     355.75     201.07     178.35     224.01       30-34 years     411.32     356.56     469.27     244.23     217.74     271.39       35-39 years     620     548.65     704.73     330.63     293.66     365.3       40-44 years     1,014.17     909.7     1,137.33     485.77     438.9     532.05       45-49 years     2,766.38     2,526.95     3,071.06     1,192.22     1,082.11     1,304.70       55+ years     8,872.68     8,173.38     9,582.98     5,268.44     4,798.71     5,719.31       76.92     years     2.6     2.23     2.95     1.91     1.68     2.16       25-29 years     3.69     3.09     4.35     2.29     2.07     2.52       30-34 years     5.5     4.7		45-49 years	127.28	87.62	172.24	82.16	60.55	108.29
15-19 years     206.15     179.49     233.19     134.79     117.79     150.88       20-24 years     234.78     204.77     264.46     173.44     152.93     193.26       25-29 years     306.77     265.03     355.75     201.07     178.35     224.01       30-34 years     411.32     356.56     469.27     244.23     217.74     271.39       35-39 years     620     548.65     704.73     330.63     293.66     365.3       40-44 years     1,014.17     909.7     1,137.33     485.77     438.9     532.05       45-49 years     1,632.90     1,484.23     1,812.97     740.92     666.95     813.84       50-54 years     2,766.38     2,526.95     3,071.06     1,192.22     1,082.11     1,304.70       55+ years     8,872.68     8,173.38     9,582.98     5,268.44     4,798.71     5,719.31       76     20-24 years     2.6     2.23     2.95     1.91     1.68     2.16       20-24 years     2.6     2.23     2.95     1.91     1.68     2.16       20-24 years     5.5		50-54 years	185.27	137.95	232.89	117.95	91.37	147.09
20-24 years     234.78     204.77     264.46     173.44     152.93     193.26       25-29 years     306.77     265.03     355.75     201.07     178.35     224.01       30-34 years     411.32     356.56     469.27     244.23     217.74     271.39       35-39 years     620     548.65     704.73     330.63     293.66     365.3       40-44 years     1,014.17     909.7     1,137.33     485.77     438.9     532.05       45-49 years     1,632.90     1,484.23     1,812.97     740.92     666.95     813.84       50-54 years     2,766.38     2,526.95     3,071.06     1,192.22     1,082.11     1,304.70       55+ years     8,872.68     8,173.38     9,582.98     5,268.44     4,798.71     5,719.31       Totop years     2.6     2.23     1.91     2.52     1.42     1.22     1.6       20-24 years     2.6     2.23     2.95     1.91     1.68     2.16       25-29 years     3.69     3.09     4.35     2.29     2.07     2.52       30-34 years     5.5		55+ years	479.33	387.33	592.34	390.15	327.53	458.62
20-24 years     234.78     204.77     264.46     173.44     152.93     193.26       25-29 years     306.77     265.03     355.75     201.07     178.35     224.01       30-34 years     411.32     356.56     469.27     244.23     217.74     271.39       35-39 years     620     548.65     704.73     330.63     293.66     365.3       40-44 years     1,014.17     909.7     1,137.33     485.77     438.9     532.05       45-49 years     1,632.90     1,484.23     1,812.97     740.92     666.95     813.84       50-54 years     2,766.38     2,526.95     3,071.06     1,192.22     1,082.11     1,304.70       55+ years     8,872.68     8,173.38     9,582.98     5,268.44     4,798.71     5,719.31       Totop years     2.6     2.23     1.91     2.52     1.42     1.22     1.6       20-24 years     2.6     2.23     2.95     1.91     1.68     2.16       25-29 years     3.69     3.09     4.35     2.29     2.07     2.52       30-34 years     5.5		15-19 years	206.15	179.49	233.19	134.79	117.79	150.88
25-29 years     306.77     265.03     355.75     201.07     178.35     224.01       30-34 years     411.32     356.56     469.27     244.23     217.74     271.39       35-39 years     620     548.65     704.73     330.63     293.66     365.3       40-44 years     1,014.17     909.7     1,137.33     485.77     438.9     532.05       45-49 years     1,632.90     1,484.23     1,812.97     740.92     666.95     813.84       50-54 years     2,766.38     2,526.95     3,071.06     1,192.22     1,082.11     1,304.70       05+ years     2,766.38     2,526.95     3,071.06     1,192.22     1,082.11     1,304.70       05+ years     2,766.38     2,526.95     3,071.06     1,192.22     1,082.11     1,304.70       05+ years     2,66     2.23     2.95     1,91     1.68     2.16       20-24 years     2.6     2.23     2.95     1.91     1.68     2.16       25-29 years     3.69     3.09     4.35     2.29     2.07     2.52       30-34 years     5.5     4.7		-						
30-34 years     411.32     356.56     469.27     244.23     217.74     271.39       35-39 years     620     548.65     704.73     330.63     293.66     365.3       40-44 years     1,014.17     909.7     1,137.33     485.77     438.9     532.05       45-49 years     1,632.90     1,484.23     1,812.97     740.92     666.95     813.84       50-54 years     2,766.38     2,526.95     3,071.06     1,192.22     1,082.11     1,304.70       55+ years     2,766.38     2,526.95     3,071.06     1,192.22     1,082.11     1,304.70       50-54 years     2,66     2.23     2.95     1.91     2.52     1.42     1.22     1.6       20-24 years     2.6     2.23     2.95     1.91     1.68     2.16       25-29 years     3.69     3.09     4.35     2.29     2.07     2.52       30-34 years     5.5     4.7     6.45     2.99     2.71     3.3       35-39 years     9.53     8.46     11.01     4.56     4.1     5.04       40-44 years     18.11     16.22 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
DALYS     35-39 years     620     548.65     704.73     330.63     293.66     365.3       40-44 years     1,014.17     909.7     1,137.33     485.77     438.9     532.05       45-49 years     1,632.90     1,484.23     1,812.97     740.92     666.95     813.84       50-54 years     2,766.38     2,526.95     3,071.06     1,192.22     1,082.11     1,304.70       55+ years     8,872.68     8,173.38     9,582.98     5,268.44     4,798.71     5,719.31       V     V     V     V     V     V     V     V     V     V       Deaths     15-19 years     2.23     1.91     2.52     1.42     1.22     1.6       20-24 years     2.6     2.23     2.95     1.91     1.68     2.16       25-29 years     3.69     3.09     4.35     2.29     2.07     2.52       30-34 years     5.5     4.7     6.45     2.99     2.71     3.3       35-39 years     953     8.46     11.01     4.56     4.1     5.04       40-44 years     18.11								
40-44 years1,014.17909.71,137.33485.77438.9532.0545-49 years1,632.901,484.231,812.97740.92666.95813.8450-54 years2,766.382,526.953,071.061,192.221,082.111,304.7055+ years8,872.688,173.389,582.985,268.444,798.715,719.31TT15-19 years2.231.912.521.421.221.620-24 years2.62.232.951.911.682.1625-29 years3.693.094.352.292.072.5230-34 years5.54.76.452.992.713.335-39 years9,538.4611.014.564.15.0440-44 years18.1116.2220.577.767.078.5345-49 years33.5330.2837.4813.7412.3615.2550-54 years65.7960.2573.1625.8423.5428.34	DALYs							
45-49 years1,632.901,484.231,812.97740.92666.95813.8450-54 years2,766.382,526.953,071.061,192.221,082.111,304.7055+ years8,872.688,173.389,582.985,268.444,798.715,719.31								
50-54 years 55+ years2,766.38 8,872.682,526.95 8,173.383,071.06 9,582.981,192.22 5,268.441,082.11 4,798.711,304.70 5,719.3115-19 years 2.0-24 years2.23 2.61.91 2.522.52 1.421.22 1.681.6 2.1620-24 years 2.5-29 years2.6 3.692.23 3.092.95 4.351.91 2.291.68 2.102.16 2.1625-29 years 30-34 years3.69 5.53.09 4.354.35 2.292.07 2.072.52 2.5230-34 years 35-39 years9.53 9.538.46 8.4611.01 1.014.56 4.14.1 5.04 4.140-44 years 45-49 years18.11 3.5316.22 3.02820.57 37.487.76 1.3747.07 12.368.53 15.2550-54 years65.79 60.2560.25 7.3.1625.84 2.5423.54 2.8.3428.34		45-49 years	1,632.90					
55+ years8,872.688,173.389,582.985,268.444,798.715,719.3115-19 years2.231.912.521.421.221.620-24 years2.62.232.951.911.682.1625-29 years3.693.094.352.292.072.5230-34 years5.54.76.452.992.713.3Deaths35-39 years9.538.4611.014.564.15.0440-44 years18.1116.2220.577.767.078.5345-49 years33.5330.2837.4813.7412.3615.2550-54 years65.7960.2573.1625.8423.5428.34		-						
20-24 years2.62.232.951.911.682.1625-29 years3.693.094.352.292.072.5230-34 years5.54.76.452.992.713.3Deaths35-39 years9.538.4611.014.564.15.0440-44 years18.1116.2220.577.767.078.5345-49 years33.5330.2837.4813.7412.3615.2550-54 years65.7960.2573.1625.8423.5428.34							4,798.71	
20-24 years2.62.232.951.911.682.1625-29 years3.693.094.352.292.072.5230-34 years5.54.76.452.992.713.3Deaths35-39 years9.538.4611.014.564.15.0440-44 years18.1116.2220.577.767.078.5345-49 years33.5330.2837.4813.7412.3615.2550-54 years65.7960.2573.1625.8423.5428.34		15-10 vegre	2 22	1 01	2 52	1 42	1 22	16
25-29 years3.693.094.352.292.072.5230-34 years5.54.76.452.992.713.3Deaths35-39 years9.538.4611.014.564.15.0440-44 years18.1116.2220.577.767.078.5345-49 years33.5330.2837.4813.7412.3615.2550-54 years65.7960.2573.1625.8423.5428.34		-						
30-34 years5.54.76.452.992.713.3Deaths35-39 years9.538.4611.014.564.15.0440-44 years18.1116.2220.577.767.078.5345-49 years33.5330.2837.4813.7412.3615.2550-54 years65.7960.2573.1625.8423.5428.34								
Deaths35-39 years9.538.4611.014.564.15.0440-44 years18.1116.2220.577.767.078.5345-49 years33.5330.2837.4813.7412.3615.2550-54 years65.7960.2573.1625.8423.5428.34								
40-44 years18.1116.2220.577.767.078.5345-49 years33.5330.2837.4813.7412.3615.2550-54 years65.7960.2573.1625.8423.5428.34	Deaths							
45-49 years33.5330.2837.4813.7412.3615.2550-54 years65.7960.2573.1625.8423.5428.34	2 cutilo							
50-54 years 65.79 60.25 73.16 25.84 23.54 28.34		· · · · · ·						
		55+ years	419.85	381.34	454.29	294.88	25.34 262.37	20.54 321.97

Stroke (dea	th and I	OALYs per 100,	000 indiv	riduals) attrib	uted to smok			etween 1990	and 2021
					1000	Ye	ear	0021	
Measure	Risk	Cause	Location	Value	1990 Lower	Upper	Value	2021 Lower	Upper
Measure	Tobacco	Stroke	Global	613.23	514.78	731.39	328.94	270.32	393.11
		Intracerebral	Global	337.56	281.82	398.47	179.2	147.04	214.88
Age- standardized	ļ	hemorrhage		557754		0,000	-//-		
DALYs rate		Ischemic stroke		209.52	169.47	255.88	126.7	101.47	155.29
		Subarachnoid hemorrhage		66.15	44.17	86.12	23.04	18.3	28.32
	]	Stroke		23.59	19.26	28.63	12.65	10.09	15.55
Age- standardized		Intracerebral hemorrhage		12.04	9.72	14.44	6.56	5.29	8.01
deaths rate		Ischemic stroke		9.48	7.5	11.79	5.42	4.2	6.79
		Subarachnoid hemorrhage		2.07	1.3	2.76	0.67	0.52	0.82
	]	Stroke		25,195,959.70	21,222,115.67	29,905,438.43	28,531,038.58	23,461,344.62	34,072,552.23
All ages DALYs		Intracerebral hemorrhage		14,220,061.80	11,917,868.79	16,732,278.02	15,617,850.27	12,811,183.17	18,749,348.99
number		Ischemic stroke		8,113,773.07	6,613,088.09	9,838,072.28	10,918,707.62	8,756,100.80	13,397,298.36
		Subarachnoid hemorrhage		2,862,124.83	1,927,963.77	3,698,457.74	1,994,480.69	1,584,808.26	2,450,625.29
	]	Stroke		897,170.27	743,246.63	1,079,898.74	1,077,804.74	865,541.39	1,320,753.78
All ages deaths		Intracerebral hemorrhage		480,491.77	394,466.35	571,225.71	565,682.36	456,626.21	689,531.94
number		Ischemic stroke		332,039.90	264,009.84	408,772.70	454,272.06	354,036.04	566,679.78
		Subarachnoid hemorrhage		84,638.59	53,557.29	112,457.49	57,850.32	45,272.63	70,501.92
	]	Stroke	Iran	287.25	226.03	353.91	141.75	112.46	173.37
Age-		Ischemic stroke		197.51	155.32	246.75	102.44	80.5	126.91
standardized DALYs rate	Ŷ	Intracerebral hemorrhage		76.43	59.93	93.34	33.69	27.35	39.98
		Subarachnoid hemorrhage		13.31	8.9	20.62	5.62	4.25	7.35
	]	Stroke		10.99	8.37	13.87	5.4	4.18	6.81
Age-		Ischemic stroke		8.11	6.09	10.34	4.17	3.15	5.34
standardized deaths rate	>	Intracerebral hemorrhage		2.49	1.93	3.07	1.08	0.87	1.31
		Subarachnoid hemorrhage		0.4	0.24	0.66	0.15	0.1	0.2
	]	Stroke		82,961.15	66,180.62	102,001.93	120,413.23	96,797.89	145,857.82
		Ischemic stroke		54,399.31	43,139.40	67,502.74	83,875.39	66,918.58	102,984.82
All ages DALYs number	>	Intracerebral hemorrhage		24,299.10	18,979.26	29,643.13	31,179.33	25,411.39	37,181.14
		Subarachnoid hemorrhage		4,262.74	2,865.42	6,566.07	5,358.51	3,997.04	7,111.73
	]	Stroke		2,629.72	2,059.43	3,251.06	4,007.45	3,159.91	4,972.31
		Ischemic stroke		1,813.14	1,416.54	2,259.41	2,981.54	2,318.20	3,778.16
All ages deaths number		Intracerebral hemorrhage		705.4	548.76	863.5	902.32	727.09	1,080.10
		Subarachnoid hemorrhage		111.18	70.97	179.65	123.59	88.37	166.42

TABLE 5

#### 169

					ABLE 5 ontinued				
					minucu	Ye	ar		
					1990			2021	
Measure	Risk	Cause	Location	Value	Lower	Upper	Value	Lower	Upper
	Smoking	Stroke	Global	484.27	416.16	560.89	258.85	219.08	305.72
Age-		Intracerebral hemorrhage		268.97	230.93	312.63	142.49	120.18	167.75
tandardized DALYs rate	}	Ischemic stroke		162.68	136.07	193.54	98.29	81.26	118.66
		Subarachnoid hemorrhage		52.62	34.39	68.23	18.07	14.72	21.86
	]	Stroke		18.08	15.18	21.38	9.69	7.92	11.68
Age-		Intracerebral hemorrhage		9.41	7.85	11.11	5.11	4.21	6.14
tandardized leaths rate	}	Ischemic stroke		7.06	5.71	8.66	4.06	3.18	4.98
		Subarachnoid hemorrhage		1.62	0.98	2.16	0.52	0.41	0.64
		Subarachnoid hemorrhage		2,279,175.93	1,505,542.37	2,936,906.63	1,567,375.46	1,277,561.95	1,897,373.81
All ages DALYs		Stroke		20,013,308.76	17,298,099.70	23,117,512.01	22,522,285.86	19,059,171.05	26,588,415.23
number	}	Ischemic stroke		6,372,605.56	5,375,527.15	7,533,254.58	8,510,889.09	7,039,200.58	10,283,724.78
		Intracerebral hemorrhage		11,361,527.27	9,776,351.41	13,171,483.00	12,444,021.31	10,494,379.50	14,653,810.23
	1	Stroke		698,404.60	592,597.39	816,395.01	829,924.27	681,059.02	998,841.59
		Ischemic stroke		252,737.32	208,023.27	305,597.68	342,674.05	271,782.20	420,041.76
All ages deaths number	>	Subarachnoid hemorrhage		66,792.93	40,811.02	88,420.32	45,069.81	35,698.52	55,899.00
		Intracerebral hemorrhage		378,874.36	319,139.32	445,177.94	442,180.41	364,995.51	529,686.84
	]	Intracerebral hemorrhage	Iran	61.21	48.64	74.34	27.05	22.63	31.82
Age- standardized DALYs rate	}	Subarachnoid hemorrhage		10.44	7.05	16.15	4.33	3.23	5.64
JAL15 Tate		Stroke		223.05	181.88	271.73	110.5	90.5	133.61
		Ischemic stroke		151.4	122.56	185.9	79.12	63.83	96.82
	]	Intracerebral hemorrhage		1.95	1.53	2.4	0.85	0.69	1.01
Age-		Stroke		8.14	6.44	10.11	4.02	3.18	5.03
tandardized leaths rate		Ischemic stroke		5.89	4.6	7.4	3.06	2.37	3.88
		Subarachnoid hemorrhage		0.31	0.18	0.5	0.11	0.08	0.15
	]	Intracerebral hemorrhage		19,538.69	15,558.91	23,696.01	25,292.68	21,221.94	29,602.59
All ages DALYs 1umber	}	Subarachnoid hemorrhage		3,348.81	2,314.25	5,118.71	4,165.54	3,074.95	5,448.99
		Stroke		65,706.56	54,028.62	79,269.13	95,184.77	78,772.18	114,576.26
	]	Ischemic stroke		42,819.06	35,103.60	52,581.70	65,726.54	53,711.23	80,076.42
	]	Intracerebral hemorrhage		565.99	446.73	690.98	720.39	597.46	848.59
All ages deaths		Stroke		2,051.20	1,649.32	2,497.06	3,056.40	2,450.34	3,760.85
number		Ischemic stroke		1,397.36	1,122.86	1,726.34	2,240.21	1,787.16	2,803.28
		Subarachnoid hemorrhage		87.86	54.99	141.14	95.8	68.36	130.39

				TAB Conti					
				Contr	maca	Ye	ear		
					1990			2021	
Measure	Risk	Cause	Location	Value	Lower	Upper	Value	Lower	Upper
-	Secondhand smoke	Intracerebral hemorrhage	Global	81.94	57.08	109.91	43.06	29.39	56.93
Age- standardized	5	Subarachnoid hemorrhage		16.39	10.57	22.97	5.84	3.91	7.85
DALYs rate		Stroke		151.84	105.34	203.71	81.15	55.07	107.4
		Ischemic stroke		53.51	36.87	72.46	32.26	21.3	43.39
-		Stroke		6.26	4.38	8.48	3.34	2.21	4.48
		Ischemic stroke		2.67	1.8	3.68	1.5	0.99	2.06
Age- standardized leaths rate	>	Intracerebral hemorrhage		3.06	2.09	4.12	1.66	1.11	2.21
		Subarachnoid hemorrhage		0.53	0.32	0.76	0.17	0.11	0.23
-		Intracerebral hemorrhage		3,432,189.56	2,398,075.82	4,581,582.95	3,726,863.06	2,545,045.41	4,925,845.1
All ages DALYs		Ischemic stroke		2,011,605.19	1,385,147.47	2,714,948.44	2,741,835.15	1,819,494.99	3,680,991.5
number	}	Stroke		6,153,487.26	4,278,033.65	8,256,919.75	6,970,263.50	4,734,823.17	9,224,428.2
-		Subarachnoid hemorrhage		709,692.51	459,845.85	985,710.58	501,565.30	336,169.32	673,382.10
-		Intracerebral hemorrhage		119,179.15	81,821.29	159,936.13	141,550.15	94,510.03	188,419.9
All ages		Ischemic stroke		88,678.46	60,524.16	121,138.38	123,790.74	81,620.64	168,952.0
leaths >	}	Stroke		229,085.83	159,149.68	307,214.49	280,052.23	185,101.25	375,638.6
-		Subarachnoid hemorrhage		21,228.22	12,913.58	30,332.19	14,711.34	9,779.85	19,921.28
-	Iran	Intracerebral hemorrhage	Iran	17.69	11.55	23.95	7.68	5.24	10.24
Age- standardized	>	Subarachnoid hemorrhage		3.31	2.00	5.14	1.47	0.97	2.07
DALYs rate		Stroke		72.40	48.11	99.80	34.98	23.25	47.02
		Ischemic stroke		51.39	33.98	71.15	25.83	17.20	34.83
1		Subarachnoid hemorrhage		0.10	0.06	0.18	0.04	0.03	0.05
Age-		Stroke		3.11	2.01	4.37	1.48	0.97	2.06
tandardized leaths rate	ĺ	Ischemic stroke		2.39	1.54	3.40	1.18	0.77	1.67
-		Intracerebral hemorrhage		0.61	0.40	0.83	0.26	0.18	0.35
-		Intracerebral hemorrhage		5,587.60	3,698.55	7,579.48	6,908.14	4,712.01	9,233.05
All ages DALYs	Į	Ischemic stroke		13,198.92	8,870.85	18,352.78	20,416.49	13,563.38	27,401.42
number	[	Stroke		19,847.32	13,355.54	27,003.77	28,697.94	19,407.57	38,348.64
-		Subarachnoid hemorrhage		1,060.79	647.04	1,625.57	1,373.30	893.84	1,942.72
-		Intracerebral hemorrhage		161.35	105.71	217.88	207.47	142.45	279.87
All ages deaths	ļ	Ischemic stroke		462.32	304.77	642.01	803.41	523.39	1,116.95
number		Stroke		650.47	433.99	890.26	1,042.21	686.44	1,436.13
		Subarachnoid hemorrhage		26.8	15.68	43.37	31.33	20.61	44.93



**Figure 2. (a)** Global age-standardized DALYs of stroke attributed to smoking per 100,000 individuals. **(b)** Global age-standardized deaths from stroke attributed to smoking per 100,000 individuals.

South Khorasan (3.75 [95% UI 2.67-5.04]; Table 7, Figure 3).

## Stroke attributed to smoking stratified by age in Iran

The highest DALYs attributed to smoking per 100,000 individuals was in those aged 55 years or older (542.17 [95% UI 423.69-675.10]), and the lowest was in Tehran (99.95 [95% UI 75.87-131.30]). More than a third of stroke-related deaths attributed to smoking occurred in those aged 55 years or older (3,124 [95% UI 2,391-3,981]; Table 8; Supplementary Figure 6).

#### **DISCUSSION**

Stroke is one of the important health challenges in the international classification of diseases.<sup>[33]</sup> This research was based on the most comprehensive epidemiological estimate of the global burden of diseases in 2021. In the first section, incidence, prevalence, DALYs, and death due to stroke in Iran and globally were estimated. In the second section, new estimates on DALYs and stroke-related deaths attributed to smoking were reported.

In 2021, stroke remained the second leading cause of death and the third leading cause

						Ye	ear		
					1990			2021	
Measure	Risk	Cause	Sex	Value	Lower	Upper	Value	Lower	Uppe
]	Tobacco	Intracerebral	Males	116.23	89.55	144.29	53.64	44.22	63.09
		hemorrhage							
	Tobacco	Intracerebral hemorrhage	Females	33.24	23.68	43.41	13.61	9.62	17.51
	Tobacco	Ischemic stroke	Males	293.41	232.48	364.09	157.24	126.12	193.9
	Tobacco	Ischemic stroke	Females	95.6	67.07	126.8	48.03	33.95	63.61
	Tobacco	Stroke	Males	428.91	339.36	527.17	218.97	176.33	265.12
	Tobacco	Stroke	Females	135.74	97.5	177.56	64.77	45.87	84.77
	Tobacco	Subarachnoid hemorrhage	Males	19.27	11.75	30.39	8.09	5.89	10.97
	Tobacco	Subarachnoid hemorrhage	Females	6.9	4.05	10.27	3.13	2.19	4.24
	Smoking	Intracerebral hemorrhage	Males	102.52	79.98	126.2	47.74	40.09	55.88
	Smoking	Intracerebral hemorrhage	Females	16.47	11.98	22.27	6.19	4.41	8.02
	Smoking	Ischemic stroke	Males	253.26	204.22	312.65	138.44	111.75	170.12
	Smoking	Ischemic stroke	Females	43.55	31.76	58.05	19.93	14.32	26.38
	Smoking	Stroke	Males	372.77	300.66	452.77	193.39	157.93	232.97
ge-standardized	Smoking	Stroke	Females	63.43	47.41	83.66	27.54	19.84	36.38
OALYs rate	Smoking	Subarachnoid hemorrhage	Males	16.99	10.49	26.65	7.21	5.26	9.85
	Smoking	Subarachnoid hemorrhage	Females	3.41	2.04	5.13	1.42	0.99	1.96
	Secondhand smoke	Intracerebral hemorrhage	Males	17.68	11.34	24.9	7.61	5.01	10.46
	Secondhand smoke	Intracerebral hemorrhage	Females	17.62	11.55	24.52	7.76	5.14	10.46
	Secondhand smoke	Ischemic stroke	Males	48.56	31.24	67.94	22.89	15.3	31.71
	Secondhand smoke	Ischemic stroke	Females	53.98	34.91	77.3	29.05	19.13	39.33
	Secondhand smoke	Stroke	Males	69.19	44.37	96.11	31.64	21.09	43.49
	Secondhand smoke	Stroke	Females	75.27	49.64	105.73	38.61	25.25	52.39
	Secondhand smoke	Subarachnoid hemorrhage	Males	2.96	1.54	4.88	1.14	0.72	1.64
	Secondhand smoke	Subarachnoid hemorrhage	Females	3.68	2.09	5.74	1.8	1.17	2.6
]	Tobacco	Intracerebral hemorrhage	Males	3.81	2.91	4.78	1.7	1.38	2.04
	Tobacco	Intracerebral hemorrhage	Females	1.08	0.76	1.42	0.46	0.32	0.61
ge-standardized	Tobacco	Ischemic stroke	Males	12.18	9.27	15.42	6.26	4.82	7.93
Deaths rate	Tobacco	Ischemic stroke	Females	4	2.75	5.44	2.09	1.4	2.86
e-standardized eaths rate	Tobacco	Stroke	Males	16.58	12.86	20.63	8.18	6.42	10.23
	Tobacco	Stroke	Females	5.27	3.65	7.05	2.63	1.77	3.55
	Tobacco	Subarachnoid	Males	0.59	0.3	0.98	0.21	0.15	0.3

				<b>TABLE 6</b> Continued					
						Ye	ear		
					1990			2021	
Measure	Risk	Cause	Sex	Value	Lower	Upper	Value	Lower	Upper
	Tobacco	Subarachnoid hemorrhage	Females	0.19	0.1	0.31	0.08	0.05	0.11
	Smoking	Intracerebral hemorrhage	Males	3.3	2.54	4.11	1.5	1.22	1.8
	Smoking	Intracerebral hemorrhage	Females	0.5	0.37	0.68	0.19	0.14	0.26
	Smoking	Ischemic stroke	Males	10.19	7.9	12.82	5.38	4.16	6.79
	Smoking	Ischemic stroke	Females	1.58	1.12	2.17	0.73	0.5	1.08
	Smoking	Stroke	Males	14	10.95	17.41	7.07	5.59	8.83
	Smoking	Stroke	Females	2.17	1.57	2.93	0.96	0.67	1.37
	Smoking	Subarachnoid hemorrhage	Males	0.51	0.27	0.84	0.19	0.13	0.27
	Smoking	Subarachnoid hemorrhage	Females	0.09	0.05	0.14	0.03	0.02	0.05
Age-standardized Deaths rate	Secondhand smoke	Intracerebral hemorrhage	Males	0.62	0.39	0.87	0.25	0.17	0.34
	Secondhand smoke	Intracerebral hemorrhage	Females	0.6	0.39	0.83	0.27	0.18	0.37
	Secondhand smoke	Ischemic stroke	Males	2.28	1.44	3.2	1.01	0.67	1.41
	Secondhand smoke	Ischemic stroke	Females	2.48	1.55	3.58	1.39	0.88	1.93
	Secondhand smoke	Stroke	Males	3	1.9	4.18	1.29	0.86	1.78
	Secondhand smoke	Stroke	Females	3.18	2.02	4.49	1.71	1.09	2.36
	Secondhand smoke	Subarachnoid hemorrhage	Males	0.1	0.04	0.17	0.03	0.02	0.05
	Secondhand smoke	Subarachnoid hemorrhage	Females	0.11	0.06	0.18	0.05	0.03	0.07
	Tobacco	Intracerebral hemorrhage	Males	19,215.58	14,753.42	23,785.35	25,078.02	20,816.71	29,612.62
	Tobacco	Intracerebral hemorrhage	Females	5,083.52	3,619.95	6,668.09	6,101.31	4,317.13	7,854.55
	Tobacco	Ischemic stroke	Males	41,856.10	33,607.86	51,453.52	64,556.68	52,308.03	78,601.95
	Tobacco	Ischemic stroke	Females	12,543.21	8,808.07	16,509.24	19,318.71	13,774.96	25,414.53
	Tobacco	Stroke	Males	64,252.05	51,507.34	78,511.98	93,526.28	75,896.26	112,357.5
	Tobacco	Stroke	Females	18,709.10	13,475.22	24,440.04	26,886.95	19,240.15	34,988.58
	Tobacco	Subarachnoid hemorrhage	Males	3,180.38	1,991.42	4,953.39	3,891.58	2,810.05	5,312.63
All ages DALYs number	Tobacco	Subarachnoid hemorrhage	Females	1,082.37	639.43	1,598.59	1,466.94	1,015.74	1,996.41
	Smoking	Intracerebral hemorrhage	Males	17,005.62	13,181.38	20,856.50	22,464.68	18,880.03	26,299.4
	Smoking	Intracerebral hemorrhage	Females	2,533.07	1,835.00	3,411.72	2,827.99	2,013.68	3,656.73
	Smoking	Ischemic stroke	Males	36,752.93	29,988.88	45,345.75	57,314.20	46,933.68	69,597.13
	Smoking	Ischemic stroke	Females	6,066.13	4,407.64	8,147.26	8,412.35	6,049.29	11,140.59
	Smoking	Stroke	Males	56,572.47	46,040.34	69,073.02	83,273.18	68,783.04	99,433.82
	Smoking	Stroke	Females	9,134.09	6,799.79	12,167.50	11,911.58	8,553.95	15,758.08
	Smoking	Subarachnoid hemorrhage	Males	2,813.92	1,781.28	4,411.94	3,494.30	2,534.76	4,774.51

			<b>TABL</b> Contir						
						Ye	ear		
					1990			2021	
Measure	Risk	Cause	Sex	Value	Lower	Upper	Value	Lower	Upper
	Smoking	Subarachnoid	Females	534.89	321.76	804.58	671.24	469.55	935.96
	U	hemorrhage							
	Secondhand smoke	Intracerebral	Males	2,898.99	1,857.25	4,109.39	3,465.88	2,293.28	4,792.02
		hemorrhage							
	Secondhand smoke	Intracerebral	Females	2,688.60	1,756.41	3,715.30	3,442.27	2,287.88	4,677.76
		hemorrhage							
All ages DALYs	Secondhand smoke	Ischemic stroke	Males	6,427.24	4,248.41	9,002.11	9,075.78	6,076.55	12,504.19
number	Secondhand smoke	Ischemic stroke	Females	6,771.69	4,353.00	9,594.44	11,340.71	7,414.45	15,496.18
	Secondhand smoke	Stroke	Males	9,808.95	6,383.56	13,602.64	13,075.67	8,677.67	17,862.42
	Secondhand smoke	Stroke	Females	10,038.36	6,536.55	13,997.60	15,622.27	10,275.38	21,110.25
	Secondhand smoke	Subarachnoid	Males	482.72	252.04	796.82	534.01	337.04	775.84
		hemorrhage							
	Secondhand smoke	Subarachnoid	Females	578.07	328.12	899.28	839.29	545.88	1,210.97
		hemorrhage							
	Tobacco	Intracerebral	Males	562.35	429.64	698.1	718.64	586.83	852.82
		hemorrhage							
	Tobacco	Intracerebral	Females	143.05	101.82	186.64	183.69	131.11	241.3
		hemorrhage					~ ~ ~ ( (		a
	Tobacco	Ischemic stroke	Males	1,406.24	1,104.83	1,750.44	2,274.14	1,784.26	2,839.56
	Tobacco	Ischemic stroke	Females	406.9	283.1	544.57	707.4	481.31	945.89
	Tobacco	Stroke	Males	2,053.97	1,630.67	2,531.50	3,084.72	2,469.78	3,784.48
	Tobacco	Stroke	Females	575.75	410.44	756.82	922.73	636.91	1,223.33
	Tobacco	Subarachnoid	Males	85.38	46.61	138.52	91.94	63.36	128.59
	T-1	hemorrhage	<b>F</b>	25.0	1/1/	20.00	21 (5	20.0	42.42
	Tobacco	Subarachnoid hemorrhage	Females	25.8	14.16	39.86	31.65	20.8	43.42
	Smoking	Intracerebral	Males	494.98	383.45	611.62	638.66	528.65	752.55
	Smoking	hemorrhage	marcs	4)4.)0	JUJ.+J	011.02	0,00.00	)20.0)	794.99
	Smoking	Intracerebral	Females	71.01	50.68	96.01	81.73	57.99	108.17
	omoning	hemorrhage	i entates	/ 1.01	90.00	70.01	01.75	21.22	100.17
	Smoking	Ischemic stroke	Males	1,214.75	969.03	1,508.62	1,973.46	1,564.20	2,468.82
All ages deaths	Smoking	Ischemic stroke	Females	182.61	130.59	247.17	266.76	187.53	376.43
number	Smoking	Stroke	Males	1,784.77	1,428.17	2,187.53	2,693.84	2,168.09	3,296.72
	Smoking	Stroke	Females	266.42	195.5	355.44	362.56	257.86	497.89
	Smoking	Subarachnoid	Males	75.05	41.3	122.06	81.72	56.79	115.23
		hemorrhage							
	Smoking	Subarachnoid	Females	12.81	7.1	20.09	14.07	9.51	19.39
	_	hemorrhage							
	Secondhand smoke	Intracerebral	Males	85.85	55.5	120.7	101.35	67.4	139.51
		hemorrhage							
	Secondhand smoke	Intracerebral	Females	75.51	49.59	105.03	106.11	69.41	144.67
		hemorrhage							
	Secondhand smoke	Ischemic stroke	Males	230.64	151.46	316.92	352.34	232.78	484.68
	Secondhand smoke	Ischemic stroke	Females	231.68	148.11	331.58	451.07	287.08	622.54
	Secondhand smoke	Stroke	Males	329.65	214.54	458.38	466.69	308.7	637.33
	Secondhand smoke	Stroke	Females	320.82	210.79	449.49	575.52	370.13	788.7
	Secondhand smoke	Subarachnoid	Males	13.16	6.16	22.52	13	7.61	19.14
		hemorrhage							
	Secondhand smoke	Subarachnoid	Females	13.64	7.26	21.87	18.33	11.37	26.61
		hemorrhage							

Death	TABIand DALYs attributed to smoking stra		ovinces b	etween 19	90 and 20	21		
		Year						
			1990		2021			
Measure	Location	Value	Lower	Upper	Value	Lower	Upper	
	Alborz	267.48	195.59	349.13	137.17	98.79	176.39	
	Ardebil	256.91	184.64	337.61	175.84	134.47	226.39	
	Bushehr	319.79	239.98	416.51	178.98	136.96	235.15	
	Chahar Mahaal and Bakhtiari	255.31	187.91	341.44	124.88	93.54	164.32	
	East Azerbaijan	305.3	227.2	394.24	148.8	109.39	190.72	
	Fars	294.71	212.2	388.73	164.18	123.63	214.74	
	Gilan	322.76	242.46	420.81	169.73	125.72	219.6	
	Golestan	336.31	244.82	443.82	207.43	162.2	264.4	
	Hamadan	322.16	238.34	429.73	162.81	123.78	207.94	
	Hormozgan	385.83	292.31	500.3	161.31	121.6	209.09	
	Ilam	228.08	168.43	296.31	132.97	98.86	170.87	
	Isfahan	217.95	159.43	291.63	117.17	86.58	152.13	
	Kerman	290.09	217.73	376.72	143.49	108.17	186	
	Kermanshah	413.59	295.31	535.13	170.6	126.2	219.24	
	Khorasan-e-Razavi	345.81	258.92	461.79	153.83	117.58	196.93	
Age-standardized	Khuzestan	311.9	230.29	399.14	177.18	135.65	223.06	
DALYs rate	Kohgiluyeh and Boyer-Ahmad	247.06	178.64	323.16	138.68	103.34	177.72	
	Kurdistan	332.58	178.04 246.45	442.57	138.08 144.19	109.94 108.45	184.93	
	Lorestan	334.2	240.4) 242.79	440.11	169.98	108.4) 129.74	218.37	
	Markazi	311.78	230.59	416.05	129.07	98.14	167.15	
	Markazi Mazandaran	243.64	230.39 175.95	326.1	129.07 144.56	98.14 110.54	184.94	
	North Khorasan		252.15	455.72	152.3	116.94 116.94	193.93	
		345.11			132.5			
	Qazvin	266.78	193.93	345.61		124.6	210.3	
	Qom	316.67	227.92	427.15	126.15	96.63	160.79	
	Semnan Sistan and Baluchistan	306.66	228.55	399.87	131.89	100.01	170.2	
		312.61	223.91	405.04	163.03	119.31	213.53	
	South Khorasan	217.45	155.08	285.57	101.32	77.11	127.88	
	Tehran	212.92	154.89	286.87	99.95 156 11	75.87	131.3	
	West Azerbaijan	312.54	226.76	402	156.11	117.84	206.53	
	Yazd	306.24	234.91	392.16	130.65	99.02	167.78	
	Zanjan	257.58	190.47	341.61	147.92	114.16	186.03	
	Alborz	10.74	7.72	14.22	5.52	3.79	7.42	
	Ardebil	9.6	6.7	12.88	6.53	4.86	8.57	
	Bushehr	12.59	9.28	16.87	7.01	5.1	9.46	
	Chahar Mahaal and Bakhtiari	9.54	6.99	12.78	4.66	3.3	6.48	
	East Azerbaijan	12.47	9.03	16.53	6.1	4.36	8.24	
	Fars	11.9	8.56	15.81	6.84	4.93	9.14	
	Gilan	12.33	8.97	16.32	6.58	4.73	8.72	
	Golestan	12.15	8.81	16.18	7.53	5.79	9.79	
Age-standardized	Hamadan	11.97	8.81	15.94	5.72	4.19	7.51	
deaths rate	Hormozgan	14.29	10.71	19.2	6.03	4.55	8	
	Ilam	8.72	6.28	11.56	5.26	3.75	6.99	
	Isfahan	8.4	5.99	11.16	4.49	3.14	6.07	
	Kerman	10.92	8.12	14.32	5.49	3.95	7.38	
	Kermanshah	15.66	11.14	20.26	6.51	4.65	8.73	
	Khorasan-e-Razavi	13.34	9.87	17.86	5.9	4.33	7.85	
	Khuzestan	11.85	8.55	15.4	6.61	4.87	8.55	
	Kohgiluyeh and Boyer-Ahmad	8.94	6.4	12.08	4.9	3.53	6.6	
	Kurdistan	12.74	9.43	16.85	5.39	3.91	7.03	

TABLE 7   Continued								
	Year							
			1990			2021		
Measure	Location	Value	Lower	Upper	Value	Lower	Upper	
	Lorestan	12.66	8.84	16.74	6.32	4.63	8.42	
	Markazi	11.94	8.82	16.1	4.64	3.48	6.28	
	Mazandaran	9.17	6.48	12.15	5.26	3.81	7.05	
	North Khorasan	12.91	9.24	17.22	5.56	4.12	7.26	
	Qazvin	10.22	7.39	13.32	6.53	4.83	8.53	
Age-standardized	Qom	12.56	8.74	17.09	4.92	3.65	6.54	
deaths rate	Semnan	11.72	8.47	15.58	5.17	3.81	6.92	
	Sistan and Baluchistan	11.66	8.08	15.25	5.34	3.84	7.23	
	South Khorasan	8.36	5.78	10.95	3.75	2.67	5.04	
	Tehran	7.93	5.62	10.81	3.85	2.72	5.24	
	West Azerbaijan	12.44	8.68	16.48	6.38	4.58	8.76	
	Yazd	12.1	9.2	15.85	5.26	3.87	7.03	
	Zanjan	9.64	6.92	12.9	5.76	4.24	7.48	
	Alborz	1,737.42	1,263.24	2,246.96	3,977.59	2,952.39	5,034.90	
	Ardebil	1,432.08	1,035.23	1,869.91	2,334.94	1,781.82	2,984.92	
	Bushehr	960.14	720.93	1,248.43	1,813.28	1,398.93	2,353.50	
	Chahar Mahaal and Bakhtiari	840.55	622.89	1,099.02	1,193.49	894.7	1,554.43	
	East Azerbaijan	5,425.63	3,997.26	7,092.35	6,375.74	4,717.16	8,096.26	
	Fars	5,028.10	3,633.35	6,649.07	8,314.92	6,240.98	10,755.84	
	Gilan	4,452.68	3,353.59	5,859.82	5,654.93	4,213.20	7,299.28	
	Golestan	2,126.11	1,552.45	2,824.42	3,829.76	3,000.98	4,816.20	
	Hamadan	2,866.09	2,103.46	3,867.87	3,206.82	2,447.93	4,105.84	
	Hormozgan	1,666.58	1,234.84	2,199.47	2,382.83	1,816.23	3,058.45	
	Ilam	419.66	308.5	544.41	757.24	577.37	966.96	
	Isfahan	4,318.00	3,149.94	5,812.12	6,936.12	5,190.03	8,909.49	
	Kerman	2,691.91	2,000.29	3,491.49	4,274.20	3,214.12	5,508.23	
	Kermanshah	3,404.98	2,443.52	4,431.30	3,682.91	2,733.78	4,674.29	
All ages DALYs	Khorasan-e-Razavi	8,276.81	6,217.13	11,011.95	9,543.05	7,272.14	12,046.64	
number	Khuzestan	4,327.74	3,170.73	5,545.03	7,515.37	5,752.03	9,458.03	
	Kohgiluyeh and Boyer-Ahmad	494.86	361.92	653.37	935.32	700.65	1,204.02	
	Kurdistan	2,024.44	1,496.37	2,717.37	2,458.16	1,844.96	3,152.84	
	Lorestan	2,342.10	1,702.37	3,072.84	2,915.02	2,235.06	3,754.53	
	Markazi	2,068.12	1,517.24	2,801.40	2,152.16	1,640.88	2,775.32	
	Mazandaran	3,239.34	2,321.56	4,337.24	6,070.20	4,626.55	7,764.07	
	North Khorasan	1,092.16	800.52	1,452.00	1,235.31	959.63	1,563.26	
	Qazvin	1,234.43	900.11	1,617.76	2,142.70	1,657.43	2,718.07	
	Qom	1,054.42	756.07	1,425.62	1,584.36	1,233.26	2,005.47	
	Semnan	878.98	654.65	1,140.22	1,004.31	769.58	1,278.21	
	Sistan and Baluchistan	1,962.60	1,425.24	2,554.77	3,194.52	2,329.80	4,199.92	
	South Khorasan	824.21	596.08	1,090.00	819.48	619.79	1,019.80	
	Tehran	9,989.00	7,337.78	13,429.77	16,196.54		21,258.39	
	West Azerbaijan	3,482.23	2,480.42	4,519.89	4,894.49	3,712.27	6,427.74	
	Yazd	1,128.41	870.08	1,445.06	1,378.37	1,048.22	1,772.11	
	Zanjan	1,171.38	863.1	1,534.18	1,639.12	1,259.18	2,079.62	
All ages deaths	Alborz	54.46	39.08	71.17	124.5	87.86	164.68	
	Ardebil	44.47	31.34	59.58	77.07	57.68	99.93	
number	Bushehr	30.05	22.08	39.45	57.74	43.12	75.77	
	Chahar Mahaal and Bakhtiari	26.42	19.15	35.54	39.03	28.09	53.66	
	East Azerbaijan	174.55	127.09	229.61	218.75	158.07	291.29	

		<b>BLE 7</b> ntinued						
		Year						
			1990			2021		
	Location	Value	Lower	Upper	Value	Lower	Upper	
	Fars	164	115.68	216.69	293.23	213.07	389.38	
	Gilan	142.87	105.09	190.78	198.08	144.31	260.7	
	Golestan	64.1	46.4	85.74	118.54	92.17	152.24	
	Hamadan	91.81	67.32	122.35	106.53	78.21	138.81	
	Hormozgan	53.72	40.49	71.29	72.54	54.27	94.28	
	Ilam	13.54	9.82	17.75	24.72	18.07	32.23	
	Isfahan	136.18	96.83	185.04	234.53	166.14	311.25	
	Kerman	86.14	62.96	112.88	134.67	98.45	177.29	
	Kermanshah	109.28	76.56	142.91	125.64	91.22	167.55	
	Khorasan-e-Razavi	266.07	198	356.08	318.47	236.95	418.21	
	Khuzestan	142.13	103.3	183.83	239.04	179.51	304.17	
	Kohgiluyeh and Boyer-Ahmad	14.5	10.31	19.29	28.27	20.57	37.29	
All ages deaths number	Kurdistan	65.73	47.8	88.1	82.17	60.07	106.82	
	Lorestan	75.25	54.02	100.4	94	70.89	124.05	
	Markazi	67	48.96	90.99	74.34	55.77	100.7	
	Mazandaran	99.97	71.66	135.71	198.01	145.36	260.53	
	North Khorasan	33.69	24.35	45.11	40.31	30.25	51.9	
	Qazvin	40.21	28.83	52.68	73.45	55.1	94.64	
	Qom	34.13	23.73	46.29	51.74	39.12	67.8	
	Semnan	29.18	21.31	38.74	34.57	25.7	46.1	
	Sistan and Baluchistan	62.01	44.2	81.47	88.23	63.63	117.24	
	South Khorasan	26.91	18.8	35.5	28.73	20.62	38.46	
	Tehran	297.66	211.99	405.61	563.34	408.23	761.7	
	West Azerbaijan	108.8	78.33	143.57	161.02	118.56	216.05	
	Yazd	37.81	28.69	48.83	48.32	35.98	63.62	
	Zanjan	37.08	26.59	49.2	57.86	43.11	75.07	

of disability among noncommunicable diseases. Although the prevalence, incidence, mortality, and disability rates of stroke globally and in Iran decreased between 1990 and 2021, the number of cases increased. Among stroke pathologies, ischemic stroke was the highest in the world and Iran. In the USA, 87% of strokes were reported as ischemic strokes.[34] More than 90% of all stroke-related deaths occurred in those aged 55 years or older. In similar studies, it was shown that the highest rate of stroke occurred in older ages,[35] and almost three-quarters of strokes occurred in those aged 65 years or older.[35] Age remains the largest risk factor for stroke.[36] Mechanisms of aging and stroke were based on changes in brain activity.<sup>[36]</sup> Since stroke is a vascular disease, it is necessary to pay attention to the effects of aging on vascular diseases and based on the study showed that "Aging was also associated

with decreased expression of endothelial nitric oxide synthase (eNOS) and increased production of inducible nitric oxide synthase (iNOS), factors that alter vascular function".<sup>[37]</sup>

Smoking was a major factor in stroke globally and in Iran. The 2019 global estimate of stroke-related factors showed that smoking was the fifth leading cause of stroke, with 25.3 million DALYs attributed to smoking.<sup>[1]</sup> Ten stroke risk factors were identified, and 88% of stroke risk factors were attributed to these; researchers stated that stroke could be prevented to a large extent.<sup>[38]</sup> The evidence for the relationship between tobacco use and stroke is well established.<sup>[39,40]</sup> Some studies reported up to six times the risk of stroke caused by smoking.<sup>[41]</sup> The effects of exposure to secondhand smoke and the risk of stroke were shown in the current study, as well as in previous studies.<sup>[41-45]</sup> The mechanisms



**Figure 3. (a)** Age-standardized DALYs of stroke attributed to smoking per 100,000 individuals stratified by provinces. **(b)** Age-standardized deaths from stroke attributed to tobacco smoking per 100,000 individuals stratified by provinces. DALYs: Disability-adjusted life years.

listed for how the relationship between smoking and the risk of stroke are extensive include carboxyhemoglobinemia, increased platelet aggregability, increased fibrinogen levels, reduced high-density lipoprotein cholesterol, and direct toxic effects of compounds, such as 1,3-butadiene, a vapor phase constituent of environmental tobacco smoke that accelerated atherosclerosis in animal models.<sup>[46]</sup> Furthermore, secondhand smoking was related to atherosclerosis as measured by B-mode ultrasound of the carotid wall,<sup>[47,48]</sup> as well as to early arterial damage as assessed by endothelium-dependent brachial artery dilatation.<sup>[49]</sup> This study shared certain limitations with the GBD Study 2021, which were previously addressed.<sup>[28,29]</sup> While smoking was a major focus, future studies could expand to include other emerging risk factors for stroke, such as dietary habits and physical inactivity, to provide a more comprehensive picture of the disease's burden.

In conclusion, this was a comprehensive study on the burden of stroke and its burden attributable to tobacco use globally and in Iran. The evidence obtained from this study, representing the most up-to-date estimates, is insightful. The findings obtained from the current study show that stroke

			TABLE 8				
Death	and DALYs att	ributed to sn	noking stratifi	ied by ages b	etween 1990	and 2021	
		Year					
			1990				
Measure	Age (years)	Value	Lower	Upper	Value	Lower	Upper
	25-29	24.37	13.22	38.87	16.26	8.96	25.39
	30-34	100.28	70.95	132.52	67.42	50.71	87.32
	35-39	159.68	119.72	207.58	94.38	71.86	121.94
DALYs rate	40-44	265.61	204.55	335.64	138.06	109.88	174.59
	45-49	408.43	311.95	529.96	196.89	149.5	246.47
	50-54	659.21	507.65	836.74	295.06	229.75	360.39
	55+	1,108.42	870.75	1,379.38	542.17	423.69	675.1
	25-29	0.29	0.16	0.47	0.18	0.1	0.29
	30-34	1.36	0.97	1.86	0.86	0.66	1.09
	35-39	2.49	1.85	3.31	1.35	1.02	1.72
Deaths rate	40-44	4.79	3.62	6.08	2.27	1.8	2.83
	45-49	8.46	6.36	10.79	3.72	2.88	4.64
	50-54	15.78	12.04	19.96	6.49	5	7.92
	55+	43.57	33.8	54.59	24.05	18.41	30.64
	25-29	1,032.19	560.14	1,646.58	1,035.51	570.58	1,617.11
	30-34	3,552.59	2,513.79	4,695.02	5,618.39	4,225.87	7,276.79
	35-39	4,432.53	3,323.13	5,762.05	8,408.05	6,401.73	10,863.35
DALYs number	40-44	5,782.13	4,452.74	7,306.47	9,863.40	7,850.22	12,473.66
	45-49	6,676.70	5,099.59	8,663.47	10,927.75	8,297.82	13,679.59
	50-54	10,387.59	7,999.39	13,185.14	14,126.85	11,000.06	17,254.84
	55+	51,097.42	40,141.06	63,588.39	70,433.28	55,041.43	87,701.75
	25-29	12.39	6.84	20.11	11.63	6.49	18.3
Deaths number	30-34	48.24	34.21	66.03	71.93	54.91	91.18
	35-39	69.22	51.31	91.92	120.34	91.24	152.85
	40-44	104.33	78.86	132.41	161.83	128.76	201.98
	45-49	138.23	103.97	176.44	206.53	159.99	257.5
	50-54	248.67	189.75	314.49	310.63	239.46	379.43
	55+	2,008.65	1,558.38	2,516.35	3,124.57	2,391.10	3,981.02

remains a noncommunicable disease with a major burden, and although its prevalence has decreased compared to previous decades, due to the increase in the population, the case of stroke has also increased. Considering the decrease in the fertility rate in the world, particularly in Iran, and the increase in the elderly population in the coming decades, the burden caused by stroke on the health system can be significant. Therefore, it is necessary to address the preventable risk factors of stroke, including tobacco use, which is a major risk factor, helping to reduce the burden of stroke.

**Data Sharing Statement:** The data sources of this study were taken from GBD 2021, which is publicly available. The data can be accessed through the links below. https://vizhub.healthdata.org/gbd-results/, https://vizhub.healthdata.org/gbd-compare/

Burden of stroke and risk attributed to tobacco smoking

**Author Contributions:** Conceptualization, extraction, analysis, writing and revision: S.A.; Conceptualization, writing and revision: M.A.K

**Conflict of Interest:** The authors declared no conflicts of interest with respect to the authorship and/ or publication of this article.

**Funding:** The authors received no financial support for the research and/or authorship of this article.

#### REFERENCES

- GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021;20:795-820. doi: 10.1016/ S1474-4422(21)00252-0.
- Rochmah TN, Rahmawati IT, Dahlui M, Budiarto W, Bilqis N. Economic burden of stroke disease: A systematic review. Int J Environ Res Public Health 2021;18:7552. doi: 10.3390/ijerph18147552.
- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204-22. doi: 10.1016/S0140-6736(20)30925-9.
- 4. Johnson AJ, Dudley WN, Wideman L, Schulz M. Physiological risk profiles and allostatic load: Using latent profile analysis to examine socioeconomic differences in physiological patterns of risk. Eur J Env Public Hlt 2019;3:em0029.
- Katan M, Luft A. Global burden of stroke. Semin Neurol 2018;38:208-11. doi: 10.1055/s-0038-1649503.
- GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 2024;23:973-1003. doi: 10.1016/S1474-4422(24)00369-7.
- Owolabi MO, Thrift AG, Mahal A, Ishida M, Martins S, Johnson WD, et al. Primary stroke prevention worldwide: Translating evidence into action. Lancet Public Health 2022;7:e74-85. doi: 10.1016/S2468-2667(21)00230-9.
- Azarpazhooh MR, Etemadi MM, Donnan GA, Mokhber N, Majdi MR, Ghayour-Mobarhan M, et al. Excessive incidence of stroke in Iran: Evidence from the Mashhad Stroke Incidence Study (MSIS), a population-based study of stroke in the Middle East. Stroke 2010;41:e3-10. doi: 10.1161/STROKEAHA.109.559708.
- Aghaali M, Yoosefee S, Hejazi SA, Shuaib A, Rahimi M, Razavinia FS, et al. A prospective population-based study of stroke in the Central Region of Iran: The Qom Incidence of Stroke Study. Int J Stroke 2022;17:957-63. doi: 10.1177/17474930211037526.
- 10. Britton J. Death, disease, and tobacco. Lancet 2017;389:1861-2. doi: 10.1016/S0140-6736(17)30867-X.
- World Health Organization. Tobacco. 2023; Available at: https://www.who.int/news-room/fact-sheets/detail/ tobacco. [Accessed: 12.07.2025]

- 12. GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: A systematic analysis from the Global Burden of Disease Study 2019. Lancet 2021;397:2337-60. doi: 10.1016/S0140-6736(21)01169-7.
- Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: A meta-analysis. Int J Cancer 2008;122:155-64. doi: 10.1002/ijc.23033.
- 14. Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: A comparison of exposures and metaanalysis of incidence and mortality risks. Eur Urol 2016;70:458-66. doi: 10.1016/j.eururo.2015.06.042.
- Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: A systematic review and metaanalysis. Arch Intern Med 2007;167:335-42. doi: 10.1001/ archinte.167.4.335.
- 16. He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease--a meta-analysis of epidemiologic studies. N Engl J Med 1999;340:920-6. doi: 10.1056/ NEJM199903253401204.
- Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989;298:789-94. doi: 10.1136/bmj.298.6676.789.
- Pan B, Jin X, Jun L, Qiu S, Zheng Q, Pan M. The relationship between smoking and stroke: A metaanalysis. Medicine (Baltimore) 2019;98:e14872. doi: 10.1097/MD.00000000014872.
- Wang X, Liu X, O'Donnell MJ, McQueen M, Sniderman A, Pare G, et al. Tobacco use and risk of acute stroke in 32 countries in the INTERSTROKE study: A case-control study. EClinicalMedicine 2024;70:102515. doi: 10.1016/j. eclinm.2024.102515.
- 20. Amiri S, Behnezhad S. Smoking and risk of sleeprelated issues: A systematic review and meta-analysis of prospective studies. Can J Public Health 2020;111:775-86. doi: 10.17269/s41997-020-00308-3.
- Amiri S, Behnezhad S. Smoking as a risk factor for physical impairment: A systematic review and metaanalysis of 18 cohort studies. J Addict Dis 2020;38:19-32. doi: 10.1080/10550887.2019.1690928.
- 22. GBD 2019 Iran Collaborators. Health system performance in Iran: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2022;399:1625-45. doi: 10.1016/S0140-6736(21)02751-3.
- 23. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;403:2100-32. doi: 10.1016/S0140-6736(24)00367-2.
- 24. GBD 2021 Fertility and Forecasting Collaborators. Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: A comprehensive

demographic analysis for the Global Burden of Disease Study 2021. Lancet 2024;403:2057-99. doi: 10.1016/ S0140-6736(24)00550-6.

- 25. Doshmangir L, Khabiri R, Gordeev VS. Policies to address the impact of an ageing population in Iran. Lancet 2023;401:1078. doi: 10.1016/S0140-6736(23)00179-4.
- 26. Danial Z, Motamedi MH, Mirhashemi S, Kazemi A, Mirhashemi AH. Ageing in iran. Lancet 2014;384:1927. doi: 10.1016/S0140-6736(14)62278-9.
- 27. Fallahzadeh A, Esfahani Z, Sheikhy A, Keykhaei M, Moghaddam SS, Tehrani YS, et al. National and subnational burden of stroke in Iran from 1990 to 2019. Ann Clin Transl Neurol 2022;9:669-83. doi: 10.1002/acn3.51547.
- 28. GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;403:2162-203. doi: 10.1016/ S0140-6736(24)00933-4.
- 29. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, Years Lived with Disability (YLDs), Disability-Adjusted Life-Years (DALYs), and Healthy Life Expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;403:2133-61. doi: 10.1016/S0140-6736(24)00757-8.
- World Health Organization. Tobacco smoke-Level 2 risk. 2024. Available at: https://www.healthdata.org/researchanalysis/diseases-injuries-risks/factsheets/2021-tobaccosmoke-level-2-risk. [Accessed: 12.07.2025]
- 31. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, Years Lived with Disability (YLDs), Disability-Adjusted Life-Years (DALYs), and Healthy Life Expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;403:2133-61. doi: 10.1016/S0140-6736(24)00757-8.
- 32. Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, et al. Guidelines for accurate and transparent health estimates reporting: The GATHER statement. Lancet 2016;388:e19-23. doi: 10.1016/S0140-6736(16)30388-9.
- 33. Shakir R. The 11th edition of the international classification of diseases and related health problems: The global impact on the future of neurology for the next generation. Turk J Neurol 2023;29:230-3. doi: 10.4274/tnd.2023.14478
- 34. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: A report from the American Heart Association. Circulation 2018;137:e67-492. doi: 10.1161/ CIR.0000000000000558.
- Yousufuddin M, Young N. Aging and ischemic stroke. Aging (Albany NY) 2019;11:2542-4. doi: 10.18632/ aging.101931.

- 36. Lucke-Wold BP, Turner RC, Lucke-Wold AN, Rosen CL, Huber JD. Age and the metabolic syndrome as risk factors for ischemic stroke: Improving preclinical models of ischemic stroke. Yale J Biol Med 2012;85:523-39.
- Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G. Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J 2003;17:1183-5. doi: 10.1096/fj.02-1049fje.
- 38. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010;376:112-23. doi: 10.1016/S0140-6736(10)60834-3.
- 39. Pan B, Jin X, Jun L, Qiu S, Zheng Q, Pan M. The relationship between smoking and stroke: A metaanalysis. Medicine (Baltimore) 2019;98:e14872. doi: 10.1097/MD.00000000014872.
- 40. Shah RS, Cole JW. Smoking and stroke: The more you smoke the more you stroke. Expert Rev Cardiovasc Ther 2010;8:917-32. doi: 10.1586/erc.10.56.
- 41. Bonita R, Duncan J, Truelsen T, Jackson RT, Beaglehole R. Passive smoking as well as active smoking increases the risk of acute stroke. Tob Control 1999;8:156-60. doi: 10.1136/tc.8.2.156.
- 42. You RX, Thrift AG, McNeil JJ, Davis SM, Donnan GA. Ischemic stroke risk and passive exposure to spouses' cigarette smoking. Melbourne Stroke Risk Factor Study (MERFS) Group. Am J Public Health 1999;89:572-5. doi: 10.2105/ajph.89.4.572.
- 43. Malek AM, Cushman M, Lackland DT, Howard G, McClure LA. Secondhand smoke exposure and stroke: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Prev Med 2015;49:e89-97. doi: 10.1016/j.amepre.2015.04.014.
- 44. Liu W, Wang B, Xiao Y, Wang D, Chen W. Secondhand smoking and neurological disease: A meta-analysis of cohort studies. Rev Environ Health 2020;36:271-7. doi: 10.1515/reveh-2020-0053.
- 45. Oono IP, Mackay DF, Pell JP. Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf) 2011;33:496-502. doi: 10.1093/pubmed/fdr025.
- 46. Penn A, Snyder CA. 1,3 Butadiene, a vapor phase component of environmental tobacco smoke, accelerates arteriosclerotic plaque development. Circulation 1996;93:552-7. doi: 10.1161/01.cir.93.3.552.
- 47. Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, McGovern P, et al. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA 1998;279:119-24. doi: 10.1001/jama.279.2.119.
- 48. Diez-Roux AV, Nieto FJ, Comstock GW, Howard G, Szklo M. The relationship of active and passive smoking to carotid atherosclerosis 12-14 years later. Prev Med 1995;24:48-55. doi: 10.1006/pmed.1995.1007.
- 49. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996;334:150-4. doi: 10.1056/NEJM199601183340303.



Supplementary Figure 1. Global age-standardized prevalence of stroke in 2021.







Supplementary Figure 3. Count estimates of pathological types of stroke in Iran.



**Supplementary Figure 4.** Age-standardized prevalence, death, and DALYs of stroke stratified by sex. DALYs: Disability-adjusted life years.



Iran (Islamic republic of), females, all ages, stroke, risk: Tobacco

**Supplementary Figure 5.** All-age DALYs and death of stroke attributed to smoking stratified by sex. DALYs: Disability-adjusted life years.



Iran (Islamic Republic of), both sexes, 35-39 years, stroke, risk: Tobacco
 Iran (Islamic Republic of), both sexes, 40-44 years, stroke, risk: Tobacco

**Supplementary Figure 6.** All-age deaths from stroke attributed to smoking stratified by ages.